Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy

Abstract: Contrast agents (CAs) play a crucial role in high-quality magnetic resonance imaging (MRI) applications. At present, as a result of the Gd-based CAs which are associated with renal fibrosis as well as the inherent dark imaging characteristics of superparamagnetic iron oxide nanoparticles, Mn-based CAs which have a good biocompatibility and bright images are considered ideal for MRI. In addition, manganese oxide nanoparticles (MONs, such as MnO, MnO$_2$, Mn$_3$O$_4$, and MnO$_x$) have attracted attention as T1-weighted magnetic resonance CAs due to the short circulation time of Mn(II) ion chelate and the size-controlled circulation time of colloidal nanoparticles. In this review, recent advances in the use of MONs as MRI contrast agents for tumor detection and diagnosis are reported, as are the advances in in vivo toxicity, distribution and tumor microenvironment-responsive enhanced tumor chemotherapy and radiotherapy as well as photothermal and photodynamic therapies.

Keywords: manganese oxide nanoparticles, MRI, multimodal imaging, contrast agent, tumor therapy

Introduction

Molecular imaging technology is of great value for tumor detection and prognosis monitoring as a result of its high accuracy and reliability for elucidating biological processes and monitoring disease conditions. Various imaging techniques which are currently in widespread use include optical imaging (OI), X-ray computed tomography (CT), positron emission tomography/single photon emission computed tomography (PET/SPECT), magnetic resonance imaging (MRI), and ultrasound (US) imaging, while multimodal imaging technologies including photoacoustic (PA) tomography are being developed.

Among these techniques, MRI has become one of the most powerful means of clinical detection and prognosis observation as a result of its non-invasive, high spatial resolution, non-ionizing radiation, and soft tissue contrast. While MRI is the best imaging technique for detecting soft tissue, the long relaxation time of water protons leads to weak differences between tissues, resulting in poor image depiction between typical and malignant tissue. Fortunately, magnetic resonance contrast agent (CA) has the ability to enhance contrast, thereby improving the sensitivity of magnetic resonance diagnosis. Approximately 35% of the clinical magnetic resonance scans require the use of CAs. Therefore, in order to obtain high-quality molecular imaging for clinical diagnosis, many researchers have explored the CAs of MRI.

In order to improve imaging contrast sensitivity, various T1- or T2-MRI CAs based on gadolinium (Gd), manganese (Mn), and iron oxide nanoparticles (Fe$_3$O$_4$...
NPs have entered clinical trials or been approved by US Food and Drug Administration. Unfortunately, these nanoparticles have been somewhat limited in their clinical application due to their intrinsic dark signals and susceptibility artifacts in MRI, which means it is difficult to make a distinction between small early stage tumors and hypointense areas. Therefore, Mn-based CAs are considered ideal substitutes due to their bright signals and good biocompatibility.

Mn-based CAs can be divided into two major categories: Mn$^{2+}$ composites and manganese oxide nanoparticles (MONs). Unfortunately, Mn$^{2+}$ complexes have short blood circulation times while high doses of Mn$^{2+}$ can accumulate in the brain, causing manganese poisoning to manifest as changes in central nervous system activity, resulting in cognitive, psychiatric, and movement abnormalities. As a result, Mn$^{2+}$ chelate is not an ideal candidate for an MR CA. However, MONs emerging in recent years have exhibited negligible toxicity and good T1-weighted contrast effects. Surprisingly, these MONs can respond to tumor microenvironments (TME), such as pH, H$_2$O$_2$ or glutathione (GSH), in order to enhance MRI, alleviate tumor hypoxia and enhance therapy treatment. Therefore, MONs have been extensively studied in the field of magnetic resonance CAs.

In recent years, the relaxivity and toxicological properties of MONs as well as the chemistry and magnetic resonance performance of responsive Mn-based CAs have been reviewed. However, according to the current literature, few reviews have been conducted specifically on the progress of MONs in both tumor imaging and enhanced therapeutic effect in the past six years. Therefore, in this review, we divided MONs into four categories: MnO, Mn$_3$O$_4$, MnO$_2$, and MnO$_x$ and reviewed their achievements as MR CAs in MRI, bimodal and multimodal imaging as well as imaging-guided tumor therapy, respectively. This review also covers surface modification, toxicity in vitro and in vivo, and the tumor microenvironment-responsive performance of MONs-based materials.

**MnO-Based Nanoparticles In Tumor Diagnosis And Therapy**

Mn(II) ion is a key factor which is necessary for MnOs to have strong MRI ability, as the five unpaired electrons in its 3d orbital can produce a large magnetic moment and cause nearby water proton relaxation. This means that MnO NPs are potential candidates for T1-weighted MR CAs. Surface coating is a common method for improving the relaxation rate of MnO NPs, such as polymer functionalization, silica coating, phospholipid modification, and so on. Additionally, researchers have recently integrated MnO NPs with other modal CAs or nanotheranostic agents to provide more comprehensive information for clinical research. Table 1 highlights some examples based on MnO nanoparticles as imaging CAs and nanotheranostic agents in vivo.

**MnO As Contrast Agents In Magnetic Resonance Imaging**

With the advantages of small volume, easy preparation, and low toxicity, MnO nanoparticles are good T1 CAs. However, MnO nanoparticles may be retained by the reticuloendothelial system and subsequently enriched in the liver and spleen, leading to Mn$^{2+}$-induced toxic effects. In order to reduce the toxicity of MnO in vivo, Chevallier and colleagues attached pegylated bis-phosphonate dendrons (PDns) to the surface of MnO, which greatly improved colloidal stability, relaxation performance ($r_1=4.4$ mM$^{-1}$s$^{-1}$, $r_2=37.8$ mM$^{-1}$s$^{-1}$, 1.41 T) and rapid excretion ability. In addition, the MnO nanoparticles with a hydrodynamic diameter of 13.4±1.6 nm were eventually discharged through the hepatobiliary pathway as feces, urinary excretion, and so on.

Polyethylene glycol (PEG) coating has the potential to significantly improve the biocompatibility and physiological stability of nanoparticles and can also be conjugated with specific polypeptides and other aptamers in order to greatly improve the targeting capacities of nanoparticles. Therefore, PEG-modified MnO has been favored by many researchers. As an example, PEG-MnO NPs with a hydrodynamic diameter of 15.08±2.67 nm synthesized by Li and colleagues had a T1 relaxation rate of 12.942 mM$^{-1}$s$^{-1}$ and a low $r_2/r_1$ ratio of 4.66 at 3.0 T, three times that of clinically used Gd-based CAs. In addition, the AS1411 aptamer introduced by covalent cross-linking not only confers the PEG-MnO nanoprobe’s ability to target 786–0 renal cancer tumor cells but can also prolong the storage time of the probe in tumor cells. Huang and...
Table 1: Representative Examples Of MnO-Based Nanoparticles As Contrast Agents And Nanotheranostic Agents In Vivo

| Single Mode Imaging Contrast Agents | Nanoheranostic agents |
|-----------------------------------|-----------------------|
| **Materials**                     | **Treatment agents**  | **Imaging-guided treatment** | **Animal model** | **Reference** |
| mPEG&cRGD-g-PAsp@MnO              | CNSs                  | MRI-guided PTT                | 4T1 tumor-bearing BABL/c mice | 14 |
| PEG-MnO                           | MWNTs                | MR and dark dye imaging-guided PTT | Mice exhibiting LNs metastases | 53 |
| MnO-TETT-FA                       | IR808@MnO            | NIR fluorescent/PA/MR imaging-guided PTT | MCF-7 cell tumor-bearing nude mice | 52 |
| MnO modified with PEG             | MNO and DTX co-loaded PTPNPs | MR and fluorescence imaging-guided chemotherapy | Human breast cancer MDA-MB-231 tumor-bearing mice | 51 |
| MnO@PVP                           | USMO@MSNs-Dox        | Dox MRI-guided chemotherapy   | HeLa cells-bearing BABL/c nude mice | 51 |
| mPEG-SA-DA@mSiO_2                 | USP@MsNSs            |                             |                    | 51 |
| M10@CNSs                          |                       |                             |                    | 51 |

Abbreviations: mPEG, methoxypolyethylene glycol; cRGD, cyclic arginine-glycine-aspartic acid; PAsp, poly(aspartic acid); mPEG&cRGD-g-PAsp, mPEG and cRGD-grafted PAsp; MRI, magnetic resonance imaging; PEG, poly (ethylene glycol); TETT, N-(trimethoxysilylpropyl) ethylene diamine tricarboxylic acid; FA, folic acid; RGD, arginine-glycine-aspartic acid; PVP, poly(vinylpyrrolidone); mPEG-SA-DA, dopamine-terminated mPEG linked with succinic anhydride; PDns, pegylated bis-phosphonate dendrons; mSiO_2, mesoporous silica; CTX, chlorotoxin; NIR, near-infrared fluorescence; PA, photoacoustic; CT, X-ray computed tomography; HMSN, hollow mesoporous silica nanoparticle; PEI, polyethylenimine; US, ultrasound; CNSs, carbonaceous nanospheres; PTT, photothermal therapy; MWNTs, multi-walled carbon nanotubes; DTX, doxorubicin; DLLNs, doxorubicin-loaded liposomes; Au@HMSN/Au&MnO-PEI | 2   |
| colleagues coated MnO nanoparticles with dopamine-functionalized PEG (mPEG-SA-DA). They verified that this approach can achieve the best hydrophilicity and higher longitudinal relaxation rate (16.14 mM⁻¹s⁻¹) when coating density reaches 6.51 mmol m⁻². In order to enhance probe targeting, mPEG&cRGD-g-PAsp@MnO nanoparticles (r₁=10.2 M⁻¹s⁻¹, r₂=62.3 M⁻¹s⁻¹, 3 T) were obtained by conjugating MnO nanoparticles and poly (aspartic acid)-based graft polymer (containing PEG and 3,4-dihydroxyphenylacetic acid groups) before being conjugated with cRGD. And the hydrodynamic diameter of the conjugated nanoparticles was about 100 nm with a polydispersity index of 0.24. The nanoprobe was high targeting and was capable of accumulating in tumors and prolonging blood circulation time. Similarly, Gallo et al functionalized MnO nanoparticles with PEGylated RGD peptides in order to target the tumor overexpressing αvβ3 integrin. The r₁ and r₂ values were calculated to be 1.44 M⁻¹s⁻¹ and 3.98 M⁻¹s⁻¹ at 9.4 T, respectively. They also investigated the effect of PEG chain length on MR imaging. These authors found that long-chain PEG molecules (5000 Dal) have the potential to lead to a higher accumulation of high integrin tumors over a long period of time (24 hours) than short-chain PEG (600 Dal). In addition, magnetic nanomaterials have been demonstrated to couple with mesoporous silicon, noble metals, carbon-based materials, and fluorophores to function more efficiently. Li et al coated MnO nanoparticles with carboxymethyl dextran (CMDex-MONPs) (r₁=0.44 M⁻¹s⁻¹, r₂=3.45 M⁻¹s⁻¹, 3.0
Chen and colleagues improved the water solubility of MnO through the use of transterified oleic acid with N-(trimethoxysilylpropyl) ethylenediamine triacetic acid (TETT) silane.\textsuperscript{34} Hu et al coated polyvinylpyrrolidone (PVP) on MnO NPs using layer-by-layer electrostatic assembly. In particular, MnO@PVP NPs can pass through the blood–brain barrier (BBB) and gradually metabolize to other sites with blood flow. This is indicated as an intravascular MRI CA ($r_1=1.937$ mM$^{-1}$s$^{-1}$, $r_2=27.879$ mM$^{-1}$s$^{-1}$, 3.0 T) and a potential application in basic neuroscience research.\textsuperscript{35} Hsu et al encapsulated MONPs with silica-F127 (PEO$_{106}$ PPO$_{70}$PEO$_{106}$) in order to make them highly hydrophilic. In addition, under the same conditions, the porous silica-PEO nanocoating layer has the ability to enhance the contrast of T1 ($r_1=1.17$ mM$^{-1}$s$^{-1}$, $r_2=30.73$ mM$^{-1}$s$^{-1}$, 7.0 T) when compared to PEG-phospholipids, dense silica, and mesoporous silica.\textsuperscript{29} In addition, the structure of MnO can affect its relaxation properties. Octagonal MnO nanoparticles have a larger surface area than spherical nanoparticles of the same size, resulting in significant enhancement of low-temperature ferromagnetic behavior. Therefore, the $r_1$ value of the 85 nm polyethylene glycol dopamine (PEG$_{600}$-DPA) coated octahedral MnO nanoparticles at a concentration of 0.194 mM is similar to that of the 17 nm spherical nanoparticles at a concentration of 0.254 mM.\textsuperscript{36}

**MnO As MR Contrast Agents In Bimodal And Multimodal Imaging**

Malignant tumors pose a serious threat to human health. Improving accurate diagnosis of tumors remains a challenging problem. In order to simultaneously obtain a tumor’s overall and local image information, as well as to realize the integration of preoperative and intraoperative diagnosis and treatment, multimodal imaging has become a research hotspot and an area for future development due to its ability to integrate various imaging modes.

T1-weighted images can be used to highlight anatomical structures, while T2-weighted images are more suitable for pathological recognition. T1-T2 dual-mode imaging combination is able to significantly improve MRI efficiency. The contrast effect of the T1-T2 dual-mode contrast agent is distance-dependent. To avoid signal quenching, the distance between T1 NPs and T2 NPs is greater than 20 nm. Nowadays, different methods for combining MnO (T1 CA) and Fe$_2$O$_4$ (T2 CA) in order to construct T1-T2 dual-mode contrast agents (DMCAs) have been extensively studied. For example, Peng and colleagues synthesized Fe$_3$O$_4$@MnO/mSiO$_2$ NPs by loading MnO into the core-shell pores of Fe$_3$O$_4$@mSiO$_2$.\textsuperscript{37} They found that when the MnO cluster was bound to the nanoeffect zone of Fe$_3$O$_4$, local induction of DMCAs can be adjusted by altering the size of Fe$_3$O$_4$ to reduce the damage of MRI to host cells. In order to verify this conclusion, they coupled an anti-CD133 antibody to the surface of Fe$_3$O$_4$@MnO/mSiO$_2$ for live brain cell imaging. Results showed a higher T1-T2 contrast imaging effect and no local damage under strong MRI magnetic field. Mn-doped Fe$_3$O$_4$ and MnO magnetic nanoparticles were then co-loaded onto an oxidized graphene (GO) sheet as T1 and T2 MR CA.\textsuperscript{38} The distance between MnO NPs and Fe$_3$O$_4$ NPs was greater than 20 nm for avoiding signal quenching.

Due to the reliability and utility of both MRI and optical imaging dual-mode in tumor diagnosis and treatment, optical/magnetic resonance dual-mode probes which are based on MnO nanoparticles have flourished. Zheng et al obtained an MR/near-infrared imaging bimodal nanoprobe (MnO-Cy5.5) by conjugating a near-infrared (NIR) dye Cy5.5 to the MnO surface. The probe was effective in infarcted myocardium accumulates. The co-localization of near-infrared fluorescence (NIRF) imaging with leukocytes and macrophages in the infarcted area means that it is a potential tool for accurate quantitative infarct areas.\textsuperscript{39} Similarly, Chen and colleagues synthesized the MnO-PEG-Cy5.5 probe, which can enhance the T1 contrast of large-volume glioma imaging.\textsuperscript{40} Hsu et al encapsulated both coumarin-545T (C545T) and MnO nanoparticles mixed loading into silica nanoshells in order to obtain a pH-responsive fluorescence and MRI dual-mode probe (MCNCs). Under neutral conditions, MnO nanoparticles have a fluorescence quenching effect for C545T, while in an acidic environment, the dissolution of MnO nanoparticles into Mn$^{2+}$ leads to a 7-fold increase in T1 contrast and fluorescence recovery. In addition, the further coupling of the dual-mode probe with folic acid (FA) conferred the ability of MCNCs to target tumor cells and delayed fluorescence recovery, resulting in an enhanced target background signal ratio and higher sensitivity after activation.\textsuperscript{41}

Some methods which do not use fluorescent dye have been introduced. Lai et al found that MnO which has been obtained through the thermal decomposition of an excess of oleic acid (oleic acid: manganese content > 2) displays
fluorescence excitation characteristics across its entire visible spectrum.\textsuperscript{42} To verify its bio-imaging performance, C6 cells were detected following surface modification of TETT, and it was found that cells exhibited blue and green fluorescence at 405 nm and 458 nm, respectively. Additionally, the longitudinal relaxation rate ($r_1$) at 7T was 4.68 mM$^{-1}$s$^{-1}$. Interestingly, Banerjee et al accidentally discovered the formation of a fluorophore when heat-treating pyrrolidin-2-one modifying MnO.\textsuperscript{43} Cell experiments initially suggested that these MnO nanoparticles support bioluminescence imaging, although the exact luminescent substances remain unclear.

Multi-modal probes enable simultaneous multi-source image processing, which results in more accurate information. In order to minimize the imaging impact of each of the components, the structure and components of the entire probe must be carefully designed. Li and colleagues synthesized Fe$_3$O$_4$/MnO-Cy5.5-CTX NPs for NIRF and T1-/T2-MR multimodal imaging in vitro and in vivo. The CTX (chlorotoxin) is a glioma ligand.\textsuperscript{44} Zhang et al designed a highly efficient US/MR/CT multimodal probe (Au@HMSN/Au&MnO).\textsuperscript{2} Large-sized Au nanoparticles were positioned in the cavity of the hollow mesoporous silica nanoparticles (HMSNs), while small-sized Au and MnO are evenly distributed in the mesoporous shell. The grayscale increment from HMSN to Au@HMSN/Au&MnO (46.9) was much larger than the sum of HMSN to HMSN/MnO (9.9) and Au@HMSN/Au (22.5), achieving 1+1≥2 of ultrasonic performance. Specifically, the polyethyleneimine (PEI)-modified Au@HMSN/Au&MnO-PEI$_{1800}$ demonstrated no obvious cytotoxicity in vitro and in vivo within 30 days. In vivo evaluation experiments found that the probe accumulated in large numbers (6.39%) in rabbit liver VX2 tumors. In addition, the contrast of US imaging was significantly enhanced, while the MR signal intensity of VX2 tumors increased from 63 to 87 and the HU value of CT increased from 75 to 130, which was much larger than that of a typical liver. Liu et al reported a tumor microenvironment (TME)-responsive MR/PA/CT trimodal tumor imaging CA, namely MnO nanocrystals wrapped in porous gold nanoclusters (MnO@Au NCs).\textsuperscript{45} PA imaging has non-invasive, high-resolution, and accurate quantification in the detection of tumor pathophysiological statuses such as microvessel density, blood oxygen saturation, and hemodynamics.\textsuperscript{46} However, the PA imaging visualization area is small. CT imaging has the characteristics of whole-body imaging and tissue-free penetration depth limitation, but it cannot distinguish the subtle differences between soft tissues.\textsuperscript{47} Magnetic resonance imaging is the best choice for soft tissue detection. Therefore, combined MR/PA/CT multi-mode imaging on a nano-platform enables more accurate tumor diagnosis. This porous layer can retard the release of Mn$^{2+}$ to enhance T1 contrast and increase PA imaging depth. Following the injection of MnO@Au NCs into HepG2 tumor-bearing mice, the PA signal was significantly enhanced and subcutaneous microvessels in the depth range of 3.5–9.3 mm were clearly observed. An intratumoral injection of MnO@Au NCs in vivo CT imaging studies was performed. The HU value at the tumor site increased from 115.3 to 657.1. Results showed that this strategy has a satisfactory enhancement effect on MR/PA/CT tumor imaging.

**MnO As MR Contrast Agents In Imaging-Guided Tumor Therapy**

Nanomedicine has the ability to greatly increase the dose and accuracy of targeted drug delivery to reduce toxic side effects, meaning it can treat tumors more effectively under non-invasive conditions. The loading of therapeutic drugs or combination of some clinical therapies to achieve simultaneous diagnosis and treatment of tumors has been extensively studied. MnO has some unique advantages for treating tumors. Water-dispersible manganese oxide nanocrystals which have been obtained by microwave-assisted methods can induce true autophagy and are independent of P53 activation.\textsuperscript{48} This autophagy enhancement helps manganese oxide nanocrystals to synergize with chemotherapeutic drugs in order to produce greater lethality against tumors. The triphenylphosphonium (PPh$_3$) is able to explore mitochondrial membrane potential. MnO@SiO$_2$-PPh$_3^+$ NPs with mitochondrial targeting were efficiently taken up by HeLa cells.\textsuperscript{49} This probe is highly specific for mitochondria. It induces severe cytotoxicity within four hours and causes cancer cell death.

In terms of combined chemotherapy, Howell and colleagues synthesized multifunctional lipid nanoparticles (M-LMNs) by encapsulating MnO in mixed cation micelles.\textsuperscript{50} In vitro studies found that M-LMNs which had been loaded with doxorubicin (Dox) or plasmid DNA was efficiently ingested by Lewis Lung Cancer (LLC1). Following intranasal administration, M-LMNs were preferentially aggregated in the lung, while MRI and release of DNA and Dox could be simultaneously performed. This suggests great potential in the treatment of lung cancer. MnSO$_4$-terminated...
mesoporous silica nanoparticles (MSNs) were calcined to obtain USMO@MSNs nanocrystals with adjustable pore sizes. The USMO@MSNs pore size was adjusted to 1.42 nm to match the chemotherapeutic drug Dox (1.37 nm), while the loading capacity was 456 mg/g. In the weak acidic environment of tumors, a simultaneous release of Mn$^{2+}$ and Dox enabled real-time monitoring of the chemotherapy efficacy of Dox by MRI. Abbasi et al co-loaded the anticancer drug docetaxel (DTX) and MnO nanoparticles into an amphiphilic polymer which contained fluorescent dyes. The longitudinal relaxation ($T_1$=2.4 mM$^{-1}$s$^{-1}$) of the probe was 2.7 times higher than that of MnO NPs. In contrast, fluorescence imaging had a positive long-term effect and could effectively load and sustain DTX, reducing the dose of drug needed to inhibit the growth of human breast cancer cells by 3–4.4 times.

In terms of photothermal therapy, MnO-coated carbon nanotubes (MWNTs-MnO-PEG) were used for the photothermal therapy of metastatic tumors. In order to examine the therapeutic effect of the nanotheranostic agent, it was co-incubated with A549 (human lung cancer) cells, after which it was found that under the laser irradiation of 3 w/cm$^2$, almost no cells survived and typical cells were not significantly reduced. Lymph nodes (LNs) metastatic mouse model of A549 cells was used for in vivo studies. The surface temperature of lymph nodes increased rapidly from 25.28°C to 55.64°C within 5 mins under laser irradiation, while the surrounding typical tissues did not increase significantly. Similarly, Xiang et al encapsulated MnO with carbon nanospheres to obtain MnO@CNSs (CNSs) with MR imaging and photothermal therapy performance. In order to enhance the phototherapy effect, Zhou and colleagues synthesized antifouling polydopamine (PDA) particles by polymers – including PEG, PEI, and polydopamine (PDA) – is currently the most common modification strategy (see Figure 1A). Examples of the PEG-modified method include Hu et al’s design of the aptamer (AS1411) conjugated MnO@SiO$_2$ core-shell nanoprobes which was used for targeted T1-MRI in mice with human cervical cancer, after which the in vivo quantitative biological distribution and the toxicity of the probe were evaluated. Probes with a T1-relaxivity of 0.53mM$^{-1}$s$^{-1}$ were modified on the surface of SiO$_2$ shelly by PEG to improve their biocompatibility. Yang and colleagues synthesized monodisperse manganese oxide NPs with a coating of silica (abbreviated as MnO$_4$@SiO$_2$) via pyrolysis at the high temperature and were aminated through the use of silylation. PEG was coupled to an MnO$_4$@SiO$_2$ surface via the amino-group attachment, followed by chemical grafting of targeting ligand FA to PEG. The final nanoprobes demonstrated good colloidal stability in RMPI plus 10% fetal bovine and exhibited the ability to target T1 magnetic resonance imaging in HeLa cells and HeLa animal tumor models overexpressing FA receptors. Wang and coworkers synthesized antifouling manganese oxide NPs using the solvothermal method in the presence of trisodium citrate, after which they modified the surface with PEG and L-cysteine. The prepared NPs had a high T1-relaxivity of 3.66 mM$^{-1}$s$^{-1}$ at 0.5 T, good aqueous solution dispersibility, good colloidal stability, and good biocompatibility. More crucially, the modification of L-cysteine allowed NPs to have a longer blood circulation time (half decay time of 28.4 hours) than those without the L-cysteine modification (18.5 hours) as well as reduced macrophages cellular uptake. This allowed NPs to

**Mn$_3$O$_4$-Based Nanoparticles In Tumor Diagnosis And Therapy**

The development of Mn$_3$O$_4$ NPs as MR CAs has also received extensive attention from researchers. In Mn$_3$O$_4$ NPs, Mn exhibits a mixed valence of +2 and +3. Compared with divalent manganese ions, higher valence states of Mn tend to exhibit lower effective T1 relaxation due to fewer unpaired electrons and less electron spin relaxation time. However, high-valent manganese ions can be activated in an intracellular reducing environment by GSH, while Mn ions are generated to increase the T1 relaxation rate. Thereby, a redox-activated T1 magnetic resonance CA can be designed.

**Mn$_3$O$_4$ As Contrast Agents In Magnetic Resonance Imaging**

In recent years, multiple Mn$_3$O$_4$-based nanoplatforms have been developed for MRI as T1 CAs. In particular, the improvement of Mn$_3$O$_4$ T1-relaxivity and biocompatibility through different surface modifications has attracted interest from researchers. Encapsulation of hydrophobic nanoparticles by polymers – including PEG, PEI, and polydopamine (PDA) – is currently the most common modification strategy (see Figure 1A). Examples of the PEG-modified method include Hu et al’s design of the aptamer (AS1411) conjugated MnO@SiO$_2$ core-shell nanoprobes which was used for targeted T1-MRI in mice with human cervical cancer, after which the in vivo quantitative biological distribution and the toxicity of the probe were evaluated. Probes with a T1-relaxivity of 0.53mM$^{-1}$s$^{-1}$ were modified on the surface of SiO$_2$ shelly by PEG to improve their biocompatibility. Yang and colleagues synthesized monodisperse manganese oxide NPs with a coating of silica (abbreviated as MnO$_4$@SiO$_2$) via pyrolysis at the high temperature and were aminated through the use of silylation. PEG was coupled to an MnO$_4$@SiO$_2$ surface via the amino-group attachment, followed by chemical grafting of targeting ligand FA to PEG. The final nanoprobes demonstrated good colloidal stability in RMPI plus 10% fetal bovine and exhibited the ability to target T1 magnetic resonance imaging in HeLa cells and HeLa animal tumor models overexpressing FA receptors. Wang and coworkers synthesized antifouling manganese oxide NPs using the solvothermal method in the presence of trisodium citrate, after which they modified the surface with PEG and L-cysteine. The prepared NPs had a high T1-relaxivity of 3.66 mM$^{-1}$s$^{-1}$ at 0.5 T, good aqueous solution dispersibility, good colloidal stability, and good biocompatibility. More crucially, the modification of L-cysteine allowed NPs to have a longer blood circulation time (half decay time of 28.4 hours) than those without the L-cysteine modification (18.5 hours) as well as reduced macrophages cellular uptake. This allowed NPs to
be utilized as effective CAs for enhancing tumor T1-weighted MRI.

PEI is another type of polymer which is commonly used for surface modification. For example, Luo et al reported that PEI-coated Mn$_3$O$_4$ NPs which had been conjugated with fluorescein isothiocyanate (FI), PEGylated FA and PEG monomethyl ether in turn were used for targeted tumor in vivo MRI. Moreover, these authors believe that the PEI-coated Mn$_3$O$_4$ NPs can be modified by PEI along with other biomolecules for multimodal biomedical imaging applications. In order to obtain T1 magnetic resonance CAs with higher r$_1$ relaxivity for positive MRI of biological systems, Sun and colleagues proposed the construction of hybrid alginate (AG) nanogels loaded with Mn$_3$O$_4$-PEI nanoparticles. Additionally, the hybrid AG/PEI-Mn$_3$O$_4$ with a high r$_1$ relaxation rate of 26.12 mM$^{-1}$s$^{-1}$ at 0.5 T...
were approximately 19.5 times higher than PEI-Mn$_3$O$_4$ NPs. Moreover, the AG/PEI-Mn$_3$O$_4$ NGs had a longer blood circulation time and better tumor MRI performance in vivo than the PEI-Mn$_3$O$_4$ NPs.

At present, both PEG and PEI modification strategies are relatively mature. However, the PEG-modified strategy creates a thick hydrophobic hydrocarbon coating shell that has the potential to hinder chemical exchange between protons and magnetic ions, resulting in a relatively low T1 relaxation rate. An alternative strategy is to use small molecules such as sodium citrate (SC) instead of oleic acid or oleylamine on surfaces of hydrophobic nanoparticles. However, the heating conditions required for the reaction may unfortunately result in the oxidation of Mn$^{3+}$ to Mn$^{2+}$ ions. Since Mn$^{3+}$ ions exhibit both lower unpaired electrons and significantly shorter electron relaxation times than Mn$^{2+}$ ions, they are not sufficient for achieving efficient water proton exchange and reducing T1 relaxation of MONs. This means it is necessary to find an optimized surface modification scheme to improve the T1 relaxation rate of MONs. Lei and co-workers designed new Mn$_3$O$_4$ nanocubes (MOC), which they transferred to aqueous media via dopamine derivatives. The optimized surface endows the MOC a high $r_1$ value (11.76 mM$^{-1}$s$^{-1}$ at 0.5 T) and a low $r_2/r_1$ ratio (1.75), avoiding the interference of T2-weighted imaging on T1-weighted imaging. Importantly, a reasonably designed pH-induced charge-switching surface can be charged negatively in the blood and positively at the tumor site. This unique function is able to improve the circulation behavior of the intelligent T1 CA in the blood and increase the uptake of cancer cells, thus realizing the accurate detection of solid tumors. On this basis, Lee and colleagues systematically studied the effects of various end-capping ligands such as carboxylate, alcohol, mercaptan, and amine with different anchoring groups on the surface functionalization of hollow manganese oxide nanoparticles (HMONs) to enhance T1 relaxation. Among all those studied, carboxylate-anchored ligands showed a significant increase in magnetization when capped on the surface of HMONs. In contrast to previous assumptions about the accessibility of surface Mn$^{3+}$ ions to water molecules, Lee et al suggest that capping-induced magnetization in HMONs is the cause of enhanced relaxation ($r_1$) values. In addition, in vivo imaging of oleate-terminated HMONs has been demonstrated in the brains of mice.

Guo and colleagues reported a liver T1-weighted MRI CA with good biocompatibility and a high T1 relaxation rate ($r_1$=11.6 mM$^{-1}$s$^{-1}$ at 3.0 T), while in vivo experiments indicated that the liver signal of mice increased by 50.1% four hours after injection with the CA. This CA was synthesized using a two-step process; after dehydration and aromatization under hydrothermal conditions, carboxylated carbon nanoparticles (CNPs) were prepared from glucose and utilized as self-sacrificing templates to deposit ultra-thin manganese oxide nanosheets from the redox reaction between CNP and KMnO$_4$. The afore-mentioned manganese oxide-based nanoprobes were synthesized using a two-step or a multi-step method. In contrast, Xiao et al proposed a one-step method for the preparation of ligand-free Mn$_3$O$_4$ NPs using liquid laser ablation. The prepared Mn$_3$O$_4$ NPs directly interact with water molecules without modification (see Figure 1B). In addition, MTT assay indicated that the cytotoxicity of Mn$_3$O$_4$ NPs was negligible. Immunotoxicity assessment showed that the Mn$_3$O$_4$ NPs slightly stimulated the immune response system, but there was no significant difference between Mn$_3$O$_4$ NPs and commercial MRI CA Gd-DTPA, and the immune response was accepted by the body. Systematic studies of intrinsic toxicity have shown that Mn$_3$O$_4$ NPs with a high relaxation rate of 8.26 mM$^{-1}$s$^{-1}$ at 3T have satisfactory biocompatibility in vitro and in vivo. The T1-weighted MR images showed that the signal of xenograft tumors was enhanced significantly after 30 mins of intravenous injection of Mn$_3$O$_4$ NPs. Hu and colleagues developed a simple, universal, cost-effective strategy for synthesizing water-soluble and amino-functionalized magnetic nanoparticles through the thermal decomposition of metal-organic precursors protected by phthalamide, followed by deprotection (Figure 1C).

Obtained amino-functionalized Mn$_3$O$_4$ NPs have a particle size of 6.6 nm and a relaxation rate of 2.74 mM$^{-1}$s$^{-1}$, and when further conjugated with FA, these can specifically target cancer cells overexpressing FA receptors.

**Mn$_3$O$_4$ As MR Contrast Agents In Bimodal And Multimodal Imaging**

MRI has the advantages of high spatial resolution and no tissue penetration depth limitation, but its low temporal resolution and low sensitivity characteristics limit its clinical application. The combination of MRI and other modal imaging can provide more adequate functional and anatomical imaging information. In order to meet the challenges of clinical diagnosis, it is necessary to develop an imaging modal combination system that can combine the advantages of single modality. T1 CAs produce a bright signal but has inherently low magnetic resonance relaxation,
while T2 CAs, especially superparamagnetic iron oxide nanoparticles, have a high detection sensitivity for lesions but are prone to magnetic artifacts and inherent dark imaging features. Therefore, an MR CA that integrates T1 and T2 contrast capabilities will enhance the sensitivity and accuracy of magnetic resonance detection. Li and colleagues first synthesized branched PEI-coated Fe$_3$O$_4$@Mn$_3$O$_4$ NPs (Fe$_3$O$_4$@Mn$_3$O$_4$-PEI NCs) by using the one-pot hydrothermal method and then modifying hyaluronic acid (HA) on the surface of particles via PEI amine. The synthesized HA-modified Fe$_3$O$_4$@Mn$_3$O$_4$ NPs showed a relatively high relaxation of $r_2$ (143.26 mM$^{-1}$s$^{-1}$) and $r_1$ (2.15 mM$^{-1}$s$^{-1}$) for targeting T1/T2 dual-mode magnetic MRI of cancer cells overexpressing the CD44 receptor. CAs reported by Li are “always on” systems that exert MR contrast effects, regardless of whether or not they approach or interact with target cells in the organism, which Kim suggested may lead to a poor target-to-background ratio. Therefore, Kim and colleagues designed a polysorbate 80 surface-modified redox-responsive heterostructure (RANs) which was composed of a superparamagnetic Fe$_3$O$_4$ core and a paramagnetic Mn$_3$O$_4$ shell as a T1/T2 dual-mode MRI CA. In aqueous environments, the Mn$_3$O$_4$ shell protects the Fe$_3$O$_4$ core from water, resulting in a low CA T2 relaxation property. The Mn center is also confined to the Mn$_3$O$_4$ structure, resulting in low water accessibility and magnetic coupling with a superparamagnetic core. The contrast effect between T1 and T2 is the OFF state. While tumor cells accumulate CAs through enhanced penetration and retention (EPR) effects, the Mn$_3$O$_4$ shell reacts with abundant GSH in the cytoplasm to dissolve into Mn$^{2+}$ ions. A great many high-spin Mn$^{2+}$ ions and exposed Fe$_3$O$_4$ cores can be used as CAs for T1- and T2- MR, respectively. Redox activation produces a significant enhancement of T1 and T2 signal contrast (ON state). In addition, Kim and colleagues performed T1- and T2-weighted MR imaging in tumor-bearing mice using effective passive tumor targeting, demonstrating that these complexes can be utilized as dual-mode magnetic resonance CAs (see Figure 2A).

Due to the high sensitivity of PET as well as the ultra-high spatial resolution and good soft tissue contrast of MRI, PET, and MRI dual-mode imaging can be currently used for clinical cancer detection, while the development of PET/T1-MRI bimodal mode probes best meets clinical demands. Zhu and colleagues synthesized PEI-coated Mn$_3$O$_4$ NPs through the solvothermal decomposition of acetylacetone manganese. PET/MRI bimodal probes were constructed using FA modification and $^{64}$Cu labeling on the surface of the amine groups Mn$_3$O$_4$ NPs. The obtained nanoprobes were successfully applied to PET/MRI imaging in small animals; compared with HeLa tumors blocked by folate receptors (FR), $^{64}$Cu-labeled Mn$_3$O$_4$ NPs showed a better tracer in HeLa tumors expressing FR 18 hrs after injection. In addition, FR-targeted Mn$_3$O$_4$ NPs showed accurate tumor T1-weighted MRI 18 hrs after injection. Zhan and team also studied PET/MRI dual-mode probes. They constructed $^{64}$Cu-labeled, antibody (TRC105)-modified Mn$_3$O$_4$ NPs for tumor vasculature targeted PET/MRI imaging (see Figure 2B and C). The anti-CD105 antibody TRC105 was the targeting ligand. CD105 has been shown to be overexpressed in many proliferating tumor endothelial cells, making it applicable for tumor diagnosis and meaning it has the potential to be used as a treatment via the use of nanomaterial. In vitro, in vivo and ex vivo experiments found good radioactivity and high specificity for the vascular marker CD105 of the Mn$_3$O$_4$ conjugated NPs ($^{64}$Cu-NOTA-Mn$_3$O$_4$@PEG-TRC105). According to T1-enhanced imaging as well as in vivo toxicity studies of the Mn$_3$O$_4$-conjugated NPs, Zhan et al believed that Mn$_3$O$_4$ NPs can be used as a safe nanoparticles for long-term targeted tumor imaging, diagnosis, and even treatment. Based on this, these authors also proposed chelator-free zirconium-89 ($^{89}$Zr, t$_{1/2}$: 78.4 hrs) labeled Mn$_3$O$_4$ NPs ($^{89}$Zr]Mn$_3$O$_4$@PEG) for in vivo PET/MRI imaging and lymph node mapping. Before that, Zhan and colleagues developed an optical/MRI dual-mode imaging probe for in vivo bimodal imaging to guide lymph node mapping (see Figure 2D and E). They constructed a hybrid optical/MRI system based on PEG-coated Mn$_3$O$_4$ NPs conjugated Cy7.5. The obtained Mn$_3$O$_4$@PEG-Cy7.5 exhibited good colloidal stability as well as good biocompatibility.

**Mn$_3$O$_4$ As MR Contrast Agents In Imaging-Guided Tumor Therapy**

Cancer is a serious threat to human life and health, and the development of the theragnostics methods is seen by researchers as having great importance. Theragnostics is a burgeoning field in medical research which allows for simultaneous diagnostic and specific therapy to enhance overall patient treatment and safety. As illustrated in Figure 3, numerous research groups have used a variety of nanotechnology approaches to contribute to the development of theragnostic agents. Wang and colleagues demonstrated that Mn$_3$O$_4$ NPs have been dissociated in response to the redox reaction with GSH in an intracellular reducing
Based on this, they constructed a multifunctional mesoporous silica-based redox-mediated nanotheranostic system using Mn₃O₄ nanolids. The assembly process for this nanotheranostic system is as follows: firstly, mesoporous silica nanoparticles (MSN) were prepared via sol-gel chemistry. MSN were then surface functionalized using carboxylic groups to ensure the loading of camptothecin (CPT) to nanochannels; finally, hydrothermally synthesized Mn₃O₄ NPs were treated using 3-aminopropyltriethoxysilane (APTES) and obtained Mn₃O₄-NH₂ nanolids were capped to MSN-COOH structure loaded with CPT to avoid premature release of cytotoxic drugs. The r₁ value of the system was calculated to be 13.39 mM⁻¹s⁻¹ at 3.0 T. Exposure of the nanotheranostic system, drug-loaded Mn₃O₄@MSN, to an intracellular GSH environment results in the dissolution of Mn₃O₄ nanolids and the intelligent release of drugs. In addition, the redox reaction dissociates the paramagnetic Mn₃O₄ NPs to Mn²⁺, which doubles the T₁ signal (r₁=25.17 mM⁻¹s⁻¹) and provides an additional opportunity to track therapeutic feedback. Zhang and co-workers designed an intelligent system for imaging diagnostics and chemotherapeutic applications. The highly integrated nanocomposite Dox-Mn₃O₄-SiNTs was assembled by uniformly distributing Mn₃O₄ NPs within mesoporous silicon nanotubes (SiNTs, 10–20 nm), while Dox was loaded into the mesoporous wall (~5 nm) of SiNTs. A series of in vitro and in vivo studies revealed that the Dox-Mn₃O₄-SiNTs nanotheranostic system has an excellent T₁-weighted MRI performance (r₁=1.72 mM⁻¹s⁻¹ at 3.0 T), which demonstrated a pH-dependent release behavior and exhibited remarkable therapeutic effects against both HeLa cells and cervical cancer xenografts.
Photodynamic therapy (PDT) is an efficient clinical therapy in which cancer cells are damaged by reactive oxygen species produced by non-toxic photosensitizers which have been exposed to specific wavelengths. Imaging-guided PDT can provide more accurate tumor localization and reduce side effects on typical tissue. Nafiujuaman and colleagues developed a ternary hybrid probe, saved as dual imaging-guided PDT agent, which consisted of MnO₂ and graphene quantum dots (GQD) linked by PDA and thiol-amine. Several stability studies of the hybrid system (GQD-PDA-MnO₂) have indicated that the link between MnO₂ and GQD can be maintained in different conditions, although partial fluorescence quenching occurs in GQD thanks to the presence of MnO₂. While these nanoparticles exhibit good biocompatibility in dark conditions, subsequent laser irradiation can trigger GQD to generate effective fluorescent emissions and reactive oxygen species, killing cancer cells and leading tumor regression. Meanwhile, GQD-PDA-MnO₂ nanoparticles also exhibited excellent optical and T1-weighted MRI capability. Ding and colleagues designed a multifunctional FA conjugated, drug (Dox)-loaded MnO₂@PDA@PEG nanotheranostic agent to be utilized for MRI-guided synergetic chemo-/photothermal (PTT) therapy. The nanotheranostic agent with an ultrahigh T1-relaxity of 14.47 mM⁻¹s⁻¹ at 1.2 T demonstrated excellent MRI ability in vitro and in vivo as well as providing overall information for tumor diagnosis and therapeutic effect monitoring. PDA can not only endow the nanotheranostics system with biocompatibility but can also act as a photothermal conversion agent for PTT and an anti-cancer drug carrier. NIR When the 808 nm near-infrared laser irradiation drug release was triggered, the nanotheranostics agent showed a significantly enhanced tumor synergistic effect, compared with both PTT and chemotherapy alone. Additionally, following the development of nanotheranostics agents, the nanotoxicity of agents has been challenged. Liu et al have developed an artificially induced degradation of ethylenediaminetetraacetic calcium disodium salt (EDTA)- and bovine serum albumin (BSA)-capped MnO₂ NPs (MONPs-BSA-EDTA) as a novel, inorganic nanomaterial for T1/T2-MRI guided PTT. Due to the high electron spin and strong NIR absorption, MnO₂ NPs not only act as a T1-T2 dual-mode MR contrast agent but also as a photothermal conversion agent. MONPs were degraded into free ultra-small MnO₂ NPs and Mn²⁺ with the introduction of ascorbic acid. Moreover, Mn²⁺, which is considered toxic to the living system, can be captured by BSA coating on the particles and EDTA loaded thereon, thereby avoiding the nanotoxicity of the inorganic nanomaterial.

**MnO₂-Based Nanoparticles In Tumor Diagnosis And Therapy**

It is well known that the growth and metabolism of tumor cells are not strictly regulated in the way that they are in typical cells, which results in the microenvironment of tumor tissues being rather different from typical tissues. On one hand, H₂O₂ is overproduced in malignant tumor cells and thus results in a significant increase in the level of H₂O₂ in a TME. On the other hand, upregulated glycolysis metabolism during tumorigenesis produces a large amount of lactic acid, resulting in a low pH value of TME. It has additionally been reported that GSH in tumor tissues is almost five times that of typical tissues and that GSH plays a key role in protecting cells from various harmful substances such as H₂O₂, superoxide, hydroxyl radical, and other reactive oxygen species. Hypoxia is a prominent feature of solid tumors which is often associated with tumor invasion, metastasis, and resistance to traditional therapies. This means that the high GSH levels and hypoxia characteristics of cancer cells have been shown to increase resistance to chemotherapy, radiotherapy, and photodynamic therapy (PDT). As reported, manganese dioxide (MnO₂) has the ability to react with GSH to reduce Mn⁴⁺ to Mn²⁺. While consuming intracellular GSH, the Mn²⁺ produced can not only enhance T1-MRI but also undergoes a Fenton reaction with H₂O₂ to form a hydroxyl radical (OH•), the most harmful reactive oxygen species (ROS). Therefore, in recent years, research on manganese dioxide nanoparticles (MnO₂ NPs) has ignited, owing to these nanoparticles’ excellent T1-weighted MRI capability and ability to respond intelligently to TME as a nanotheranostic agent.

**MnO₂ As Contrast Agents In MRI And Cellular GSH Detection**

MRI plays a key role in clinical detection, especially soft tissue. Traditional magnetic resonance CAs tend to be “always on” regardless of whether they are close to or interact with the target cell, which may result in a poor signal-to-noise ratio. Recently, studies have found that MnO₂ can enhance the contrast of magnetic resonance signals in response to endogenous stimuli such as pH, GSH. It has been challenged. Liu et al have developed an artificial...
have made deliberate achievements in the activatable magnetic resonance CAs of MnO$_2$. Zhao and colleagues reported a dual-activatable fluorescence/MRI bimodal nanoprobe which was based on MnO$_2$ nanosheet-Cy5 labeled aptamer nanoparticles for tumor cell imaging. In this dual-mode imaging system, MnO$_2$ nanosheets act as a nanocarrier to deliver aptamer, a fluorescence quencher, as well as an intracellular GSH-activated T1/T2-MRI CA (see Figure 4C). When the aptamer does not target cells, neither the fluorescence signals nor the MRI contrast of nanoprobes were activated. Conversely, once the target cells exist, the binding of aptamers to their targets will lead to a decrease in the adsorption of aptamers on MnO$_2$ nanosheets, resulting in partial fluorescence recovery (see Figure 4B), irradiation of target cell, and the promotion of endocytosis of nanoprobes to the target cell. Following endocytosis, GSH reduced MnO$_2$ nanosheets to further activate the fluorescent signal and produce many Mn$^{2+}$ ions suitable for MRI. Moreover, the reduced Mn$^{2+}$ ions exhibited both 48-fold and 120-fold enhancements in the longitudinal relaxation rate $r_1$ and the transverse relaxation rate $r_2$ when compared to the MnO$_2$ nanosheets. This platform promotes the development of various activatable fluorescent/MRI bimodal imaging for cells.

For clinical diagnosis, in vitro evaluation of nanoprobes is not sufficient. Based on this, Shi and colleagues reported a GSH-activated Ru(BPY)$_3$@MnO$_2$ bimodule phosphorescence/MR imaging nanoprobe for the determination of GSH in vitro and in vivo (see Figure 4D). As previously described, MnO$_2$ nanosheets are both phosphorescent quenchers and GSH-responsive MR CAs. After being triggered by GSH, MnO$_2$ nanosheets can be rapidly reduced to Mn$^{2+}$ ions, which leads to enhancement of the T1- and T2-weighted MR signals ($r_1$ increased from 0.11 to 9.33 mM$^{-1}$s$^{-1}$, and $r_2$ increased from 0.16 to 48.77 mM$^{-1}$s$^{-1}$ at 0.5 T) while recovering the phosphorescence of the Ru(II) complex. Since the enhancement factor of $r_2$ (85 folds) is 2.6 times higher than that of $r_1$ (305 folds), this means that when Ru(BPY)$_3$@MnO$_2$ NPs are used as T2-MR contrast agents, a higher signal-to-noise ratio can be obtained. The GSH concentration can be quantified by phosphorescence and MR. The time-gated luminescence (TGL) assay of GSH in human
serum as well as the visualization of endogenous GSH in zebrafish and tumor-bearing mice in both phosphorescence and MR imaging modes confirmed that the prepared nanoprobes have good biocompatibility and fast response as well as a high sensitivity and selectivity to GSH. Moreover, Duan and colleagues constructed a core-shell Fe$_3$O$_4$@C@MnO$_2$ nanoprobes via an in situ self-reduction method which was used as a pH-responsive T1–T2* dual-modal MRI contrast agent (Figure 4E). The release rate of Mn$^{2+}$ ions in acidic PBS with pH of 5.0 is approximately 10 times that of pH 7.4, which promotes the release of synthesized nanoparticles in the acidic environment of tumors. Following intravenous injection of Fe$_3$O$_4$@C@MnO$_2$ NPs for 24 hours, the T1 MRI signal in the tumor area was significantly enhanced by 127% compared with prior to injection. At the same time, the T2 MRI signal was weakened to 71%. Therefore, the Fe$_3$O$_4$@C@MnO$_2$ NPs are able to significantly increase the accuracy of the diagnosis and can be expected to develop as a clinical, multi-diagnostic nanoplatform.

**MnO$_2$ As MR Contrast Agents In Imaging-Guided Tumor Therapy**

MnO$_2$ NPs For Enhanced Chemotherapy And MRI

Chemotherapy is a traditional cancer treatment which damages healthy cells while killing cancer cells. It has many side effects. Moreover, hypoxia, a major characteristic of most solid tumors, not only promotes the invasiveness and metastasis of malignant cells but is also associated with resistance to radiation and chemotherapy. This means that a major challenge for enhancing the therapeutic effects and minimizing the side effects of chemotherapy is the need to achieve on-demand drug release and alleviate tumor hypoxia. As previously reported, MnO$_2$ nanoparticles have received extensive researcher attention due to their high reactivity to hydrogen peroxide for producing O$_2$ and their response to pH decomposition into Mn$^{2+}$, which can be used as MR CAs.

Many researchers have made significant contributions to the construction of MnO$_2$-based smart drug delivery systems (see Table 2). Among these, Song and colleagues reported on Dox loading, HA-modified and mannan conjugated MnO$_2$ nanoparticles (Man-HA-MnO$_2$ NPs) for targeting 4T1 mouse breast cancer cell imaging and enhancing chemotherapy. The high accumulation of tumor-associated macrophages (TAMs) in hypoxic regions of solid tumor as well as the high reactivity of MnO$_2$ NPs toward H$_2$O$_2$ led to simultaneous generation of O$_2$ and the regulation of pH to effectively mitigate tumor hypoxia. In addition, HA not only serves as a target but can also reprogram anti-inflammatory, pro-tumor M2 TAM into pro-inflammatory, anti-tumor M1 macrophages to further enhance the resultant nanoparticles to reduce tumor hypoxia and regulate chemoresistance. At the same time, Mn$^{2+}$ ions released by the reaction of Man-HA-MnO$_2$ NPs with H$_2$O$_2$ significantly enhanced both the tumor imaging and the detection performance of T1 and T2-MRI. Inspired by the biological process of KMnO$_4$ disinfection, Pan et al prepared a multifunctional BSA-MnO$_2$ nanoplatform which had a uniform size of less than 10 nm, excellent colloid stability, and high T1 relaxation rate of 7.9 mM$^{-1}$s$^{-1}$ at 0.5 T by drug–substrate interaction strategy. The BSA-MnO$_2$ nanoprobe can not only be used as a high-performance MRI agent for tumor and renal imaging but also as a MRI-guided photothermal and chemotherapeutic agent when loaded with indocyanine green and paclitaxel, respectively. Pan’s work provides a new method for the development of therapeutic agents. In Zhang’s study, MnO$_2$/Dox-loaded albumin nanoparticles (BMDN) were fabricated as a theragnostic agent for cancer MRI and a reversing multidrug resistance (MDR) tumor chemotherapy. MDR hinders the effects of chemotherapy. At present, nanocarriers are a potential means for overcoming tumor MDR, while albumin has been extensively studied as a hopeful drug carrier for nanocarrier construction due to both its excellent biocompatibility and low immunogenicity. Additionally, albumin can promote the delivery of BMDN to tumor cells, enhance cellular uptake, achieve on-demand drug release, and reduce tumor hypoxia through interaction with albumin receptors overexpressed on cancer cells. The weak acidic response of BMDN promotes the release of Mn$^{2+}$, resulting in enhanced T1-weighted imaging both in vitro and in vivo.

In order to achieve simultaneous accurate diagnosis and effective treatment of hypoxic tumors, Song and colleagues designed and synthesized a versatile rattle-structure nanotheranostic agent, with an up-conversion nanoparticle (UCNP) as the core wrapped in hollow mesoporous silica, Dox loaded in the cavity, a hypoxia-sensitive MnO$_2$ nanosheet atop the mesopores, as well as PEG and DOTA ligands conjugated onto the outer surface of the nanoparticles. MnO$_2$ nanosheets can be degraded to Mn$^{2+}$ ions in various acidic TME caused by varying degrees of hypoxia, while the resulting Mn$^{2+}$ ions can be captured by DOTA for real-time T1-MRI diagnosis of hypoxic tumors. In addition, the nanoplatform can on-demand release Dox and supplement O$_2$ to result in both normoxia- and hypoxia-sensitive chemotherapy with a single drug.
Table 2 Summary Of The Properties Of Nanoplatforms Based On Manganese Oxide-Enhanced Chemotherapy Reported In Recent Years. Classification Of Materials As A pH Response Does Not Preclude Its Response To Other Features Of The Tumor Microenvironment And Vice Versa. Classification Is Based On Evidence In Each Reference

| Nano-Structure          | Responsive | Drug   | $r_1(r_2)$ Off (mM$^{-1}$s$^{-1}$) | $r_1(r_2)$ On (mM$^{-1}$s$^{-1}$) | B (T) | Tumor Model                                                                 | Reference |
|-------------------------|------------|--------|----------------------------------|----------------------------------|-------|-----------------------------------------------------------------------------|-----------|
| PEG-MnO$_2$ nanosheets  | pH         | Dox    | 0.007                            | 4.0                              | \    | 4T1 tumor-bearing nude mice (T1-MRI) MCF-7/ADR cancer cells (chemotherapy) | 86        |
| Man-HA-MnO$_2$ NPs      | H$_2$O$_2$/pH | Dox    | 0.12 (0.41)                      | 7.96 (45.05)                     | 9.4   | 4T1 tumor-bearing mice                                                      | 87        |
| MnO$_2$/HA nanosheets   | Redox/pH   | CDDP   | 1.3417                           | 0.3803                           | 0.5   | A549 tumor-bearing mice                                                    | 88        |
| MnO$_2$-PEG-FA nanosheets | Redox/pH | Dox    | 0.38                             | 2.26                             | 0.5   | Hela tumor-bearing mice                                                    | 89        |
| BSA-MnO$_2$ NPs         | \          | PTX    | 7.9 (BSA-MnO$_2$) 13.9(BSA-MnO$_2$-PTX) | \                               | 0.5   | 4T1 tumor-bearing mice                                                    | 90        |
| BSA-MnO$_2$ NPs         | pH         | Dox    | 4.762 (BSA-MnO$_2$) 11.794 (BSA-MnO$_2$-Dox) | \                               | 1.5   | MCF-7/ADR tumor-bearing mice                                               | 91        |
| MnO$_2$ NPs             | H$_2$O$_2$/pH | ANPs-PTX | 0.13                             | 2.34                             | 7     | CT26 tumor-bearing mice                                                    | 92        |
| HMSN$s@$MnO$_2$/apt NPs | GSH/pH     | Dox    | 1.68                             | 9.25                             | 3     | NHDFs and HeLa cells                                                      | 93        |
| MS@MnO$_2$ NPs          | H$_2$O$_2$/GSH  | CPT   | 0.50                             | 6.91                             | \    | U87MG tumor-bearing mice                                                   | 80        |
| UCNPs@MnO$_2$ NPs       | GSH/pH     | Dox    | 0.41                             | 4.48                             | \    | HeLa cells                                                                | 94        |
| NaYF$_4$@Yb, Tm@NaYF$_4$@hmSiO$_2$@MnO$_2$@DOTA NPs | pH         | Dox    | 0.112                            | 1.137                            | 3     | Hela tumor-bearing mice                                                    | 95        |

Abbreviations: Man, mannan; HA, hyaluronic acid; NPs, nanoparticles; CDDP, cisplatin (cis-diaminedichloroplatinum); BSA, bovine serum albumin; PTX, paclitaxel; ANPs-PTX, albumin-bound paclitaxel nanoparticles; HMSN$s$, hollow mesoporous silica nanoparticles; apt, aptamers; GSH, glutathione; MS, mesoporous silica; CPT, camptothecin; UCNPs, upconversion nanoparticles; hmSiO$_2$, hollow mesoporous silica; DOTA, Tetrazedanum.
Recently, efforts have been made to develop ROS-based cancer therapeutic strategies, particularly chemodynamic therapy (CDT) which uses iron-mediated Fenton reactions. Unfortunately, overexpressed GSH in cancer cells has the ability to clear ·OH, which greatly reduces CDT efficacy. Based on this, Lin et al were the first to report a self-reinforced CDT nanomaterial based on MnO₂, which proposes Fenton-like Mn²⁺ delivery capacity as well as GSH depletion characteristics. These authors synthesized camptothecin-loaded, MnO₂-coated mesoporous silica NPs (MS@MnO₂-CPT) for MRI-monitored chemo-chemodynamic synergistic cancer treatment. Once cancer cells take up the MS@MnO₂-CPT NPs, the MnO₂ shell reacts with GSH to reduce Mn⁴⁺ ions to Mn²⁺ ions. While consuming endogenous GSH in the physiological medium rich in HCO₃⁻, the produced Mn²⁺ not only enhances T₁-MRI but also undergoes a Fenton reaction with H₂O₂ to form OH and so enhance CDT.

**MnO₂ NPs For Enhanced Photodynamic Therapy And MRI**

PDT is a non-invasive tumor replacement therapy in which a photosensitizer reacts with the surrounding oxygen to generate a highly active singlet oxygen and so attack internal biomolecules (such as DNA and biological membrane) under laser irradiation at a specific wavelength, resulting in damage to or death of cells. Unfortunately, the hypoxic environment of tumors along with the ability of overexpressed GSH to scavenge ROS and the short diffusion length of lasers are all obstacles to the clinical application of PDT. As a result of its typical physicochemical properties, the emerging two-dimensional MnO₂ nanosheets have been studied extensively in enhanced PDT. Crucially, based on the fact that MnO₂ nanosheets can react with intracellular GSH to reduce the amount of GSH, Meng and colleagues designed and synthesized an aptamer-conjugated, Dox and Chlorin e6 (Ce6)-loaded, MnO₂ nanosheets grafted, two-photon dye-doped mesoporous silica nanoparticle for GSH-responsive fluorescence/MR bimodal cellular imaging as well as targeted chemotherapy and PDT. Additionally, in acidic and H₂O₂-rich tumor microenvironments, MnO₂ nanosheets can be reduced to Mn²⁺ while O₂ can be formed by the following formula, thus reducing hypoxia in the tumor site:

\[
\text{MnO}_2 + 2\text{H}^+ \rightarrow \text{Mn}^{2+} + \text{H}_2\text{O} + 1/2\text{O}_2
\]

\[
\text{MnO}_2 + \text{H}_2\text{O}_2 + 2\text{H}^+ \rightarrow \text{Mn}^{2+} + 2\text{H}_2\text{O} + \text{O}_2
\]

Many researchers have made achievements in this area. Sun and colleagues constructed a smart pH/H₂O₂-responsive nanoplatfrom to be utilized for self-enhanced upconversion luminescence/MR/CT-guiding diagnosis and PDT treatment. This was based on a core-shell-shell structure of Ce6-sensitized up-converted nanoparticle-loaded honeycomb manganese oxide (hMnO₂) nanospheres. Liu et al synthesized BSA-stabilized MnO₂ nanostructures (BMnNSs), after which the photosensitizer 2-devinyl-2-(1-hexyloxyethyl) pyropheophorbide (HPPH) was conjugated onto BMnNSs surface. Owing to the generation of O₂ following the reaction of MnO₂ nanosheets with H₂O₂, the BMnNSs-HPPH showed a significantly enhanced tumor growth inhibition when compared with HPPH. Similarly, in order to overcome hypoxia and improve the photodynamic effects of bladder cancer, Lin and colleagues prepared HSA-MnO₂-Ce6 NPs. The O₂ production of NPs in vivo and in vitro was investigated, while the oxygen content of the in situ bladder cancer increased 3.5-fold following injection of HSA-MnO₂-Ce6 nanoparticles when compared with pre-injection.

To prevent the premature release of photosensitizer (PS) and increase oxygen concentration in solid tissues, Ma and colleagues developed an acidic H₂O₂-response core-shell O₂-elevated PDT nanoplatform through the use of a MnO₂ shell to encapsulate a SiO₂-methylene blue core with a high PS payload. Following the intravenous injection of nanoparticles, the external MnO₂ shell stops PS leaking into the blood until it reaches tumor tissue, avoiding phototoxicity to healthy cells. Acidic H₂O₂ in the tumor environment triggers the formation of O₂ by MnO₂ while it reduces Mn⁴⁺ to Mn²⁺, meaning it can selectively perform MRI while monitoring tumor therapy. For pH/H₂O₂-driven fluorescence/MR dual-mode guided cancer PDT, Liu constructed a black phosphorus/MnO₂ nanoplatform. In order to endow the specificity of nanoparticles for targeting tumors to enhance PDT, as reported by He, the AS1411 aptamer was anchored to the surface of large pores silica nanoparticles in which MnO₂ nanoparticles were grown in situ. Zhu et al constructed a multifunctional therapeutic nanoplatfrom through the integration of the nanoscale metal-organic framework (NMOF), BSA, sulfadiazines (SDs), and MnO₂ into a system. Porphyrins not only participate in the formation of NMOF as organic ligands but also act as photosensitizers. BSA is an ideal vehicle for endowing the multifunctional nanoplatfrom with excellent biocompatibility and long circulation. SDs were used to provide active targeting of overexpressed carbonic anhydrase IX (CA IX) in tumor...
cells. In addition, the nanoplatform can alleviate tumor hypoxia by downregulating CA IX and catalyzing H$_2$O$_2$ to produce O$_2$, which significantly enhances the PDT effect. This can be confirmed by the photocytotoxicity of 4T1 cells and the reduced tumor volume. PDT is an effective strategy for eliminating primary tumors, but its effect on metastasis and recurrence is not obvious. In order to achieve oxygen-boosted immunogenic PDT in metastatic triple-negative breast cancer (mTNBC), Liang and colleagues designed a core-shell gold nanocage@manganese dioxide (AuNC@MnO$_2$) nanoparticle as a tumor microenvironment pH/H$_2$O$_2$ responsive oxygen generator and a NIR-triggered ROS producer. The nanoplatform does not just achieve fluorescence/PA/MR multimodal imaging-guided O$_2$-enhanced PDT for destroying primary tumors effectively, but can also induce immunogenic cell death with the release of a damage-related molecular pattern, subsequently inducing dendritic cell maturation and effector cell activation, thus arousing the systemic anti-tumor immune response against mTNBC, work which has made it possible to prevent tumor metastasis.

Hao and Chu state that once the NPs of the MnO$_2$ shell-coated photosensitizer are taken up by the tumor cells, the endogenous H$_2$O$_2$ is catalyzed by the MnO$_2$ shell to produce O$_2$. At the same time, overexpressed GSH promotes the degradation of MnO$_2$ to Mn$^{2+}$ ions to enhance MRI. Fortunately, the reduction in GSH and generation of O$_2$ demonstrate synergistic enhanced PDT to improve anti-tumor efficacy in vitro and in vivo. The TME-responsive MnO$_2$ in this nanoplatform can generate oxygen to alleviate hypoxia. In addition, enhanced photosensitizer yield and elevated oxygen are conducive to the ultimate therapeutic effect. Based on the MnO$_2$ shell-enhanced PDT, Hu et al loaded Dox on the designed nanoplatform to realize a tumor microenvironment-responsive multimodal imaging-monitoring chemo-photodynamic therapy. In contrast, Bi and colleagues used an MnO$_2$ shell as the carrier of platinum(IV) (Pt(IV)) prodrugs, while intracellular GSH simultaneously reduced MnO$_2$ and Pt(IV) prodrugs to achieve GSH-responsive MRI and drug release. Interestingly, as illustrated in Figure 5A, Zhang and colleagues developed nanocomposite, upconversion nanoparticles (UCNPs)@TiO$_2$@MnO$_2$, to overcome the deficiencies of PDT with insufficient oxygen, inefficient ROS generation, and low light penetration depth. Once the nanoplatform was taken up by tumor cells, intracellular H$_2$O$_2$ was...
catalyzed by MnO₂ to generate O₂ in situ. Given the degradation of MnO₂ and 980 nm NIR laser irradiation, exposed UNCPs can effectively convert NIR into ultraviolet light to activate TiO₂, after which they catalyze the splitting of H₂O to produce toxic ROS (’O₂ and ·OH) for deep tumor treatment. In addition, the by-product of water-splitting, superoxide anion radicals (O₂⁻), can be catalyzed using intracellular superoxide dismutase (SOD) to generate more H₂O₂ and O₂. This cyclic reaction allows both O₂ and ROS to be regenerated by decomposition of MnO₂, while upconversion luminescence and MR imaging are activated in turn, which can significantly improve PDT efficiency and tumor imaging ability (see Figure 5B and C). This has great potential in antitumor.

MnO₂ NPs For Enhanced Photothermal Therapy And MRI

Photothermal therapy (PTT) is a new cancer treatment research technology which uses nanomaterials to convert near-infrared light energy into thermal energy ablation tumor.¹¹⁵ The therapy has attracted great attention in recent years due to its remarkable advantages, such as being non-invasive, leading to a rapid recovery time and high space-time control.¹¹⁶ Imaging probes are a key component of theranostics which can report the presence of tumors as well as monitoring and evaluating therapeutic effects.¹¹⁷ MnO₂, a magnetic resonance CA which responds to tumor microenvironment, is widely used in MRI-guided PTT.

Pan and colleagues synthesized a nanotheranostic agent for the cross-linking of indocyanine green on BSA-stabilized MnO₂ surface (BMI).¹⁰⁰ This BMI has an ultrahigh T1 relaxation rate of 70.6 mM⁻¹ s⁻¹ at 0.5 T. Tumors of 4T1 cells-bearing Balb/c mice completely disappeared after 13 days of intratumoral administration and irradiation with 808 nm laser at a power of 0.5 W cm⁻². For the first time, as shown in Figure 6A, Liu and colleagues proposed that ultrathin 2D MnO₂ nanosheets have T1-weighted magnetic resonance imaging capabilities of pH and redox response (see Figure 6B), and the ultrathin 2D MnO₂ nanosheets also have inherently high photothermal conversion capability (η: 21.4%), in vitro and in vivo photothermal experiments systematically demonstrated that 2D MnO₂ nanosheets have a high PTT efficiency in response to external near-infrared radiation for inhibiting tumor growth (see Figure 6C).¹¹⁸ In view of the excellent physicochemical properties of MnO₂ as well as the large size of 2D MnO₂ nanosheets, Fu et al reported a simple method for the growth of MnO₂ shells on various cores which are mediated by cationic polyelectrolytes.¹¹⁹

The Cu₂-xSe@MnO₂ nanoparticles which have been synthesized by this method show triple-enhanced magnetic resonance contrast in the tumor environment, while the Cu₂-xSe

---

Figure 6 (A) Schematic illustration of synthetic procedure for MnO₂-SPs nanosheets and their specific functions for tumor theranostics with TME sensitivity. (B) T1-weighted MR imaging of MnO₂-SPs in buffer solution at differing pHs (6.0 and 5.0) and differing GSH concentrations (2.5 and 5.0 mM) following incubation for 2 hours at 37°C. (C) Time-dependent tumor-size curves following different treatments. Reproduced from Liu Z, Zhang SJ, Lin H, et al. Theranostic 2D Ultrathin MnO₂ Nanosheets with Fast Responsivity to Endogenous Tumor Microenvironment and Exogenous NIR Irradiation. Biomaterials. 2018;155:54–63.¹¹⁸ Copyright © 2017, with permission from Elsevier.

Abbreviation: SP, soybean phospholipid.
core has strong absorption in second near-infrared (NIR II) window, demonstrating excellent PTT effect in vivo and in vitro. Peng and colleagues developed Prussian blue/MnO$_2$ hybrid nanoparticle of less than 50 nm using a one-pot method for PA/T1/T2 MR three-mode imaging-guided oxygen-regulated PTT in breast cancer. In view of the heterogeneous heat distribution in tumor tissues and the rapid heat shock protein (HSP) production which leads to PTT treatment resistance and reduced therapeutic efficacy, it is urgent that we design versatile nanoparticles which can integrate PTT with other therapies for synergistic treatment. Based on this, Jin et al constructed a novel theragnostic agent, Co$_2$P@mSiO$_2$@Dox−MnO$_2$, for pH-activated T1/T2 dual-modal magnetic MRI-guided chemo-photothermal synergistic therapy both in vitro and in vivo. In a weak acidic tumor environment, the MnO$_2$-gated dissolution not only enhanced T1-weighted MRI but also achieved on-demand drug release. This stimuli-responsive nanoagent provided more accurate diagnostic information, hugely improved the therapeutic effect and effectively reduced side effects.

In terms of chemo-photothermal synergistic therapy, Li and colleagues designed poly(ethylene glycol)thiol (PEG-SH) modified CuS-Au-MnO$_2$ ternary Janus nanoparticles (JNPs). In these ternary JNPs, the pH-responsive mesoporous MnO$_2$ acted not only as a T1 magnetic resonance CA but also as a carrier for the hydrophobic drug celestrol (CST). In addition, Au endowed ternary JNPs with CT imaging capability, and the localized surface plasmon resonance (LSPR) coupling effect of CuS surface and Au core enabled it to perform hyperthermia at 1064 nm in the NIR-II window to ablate deep tissue tumors. Similarly, Zhang and colleagues reported a GSH-activated nanoagent, SiO$_2$@Au@MnO$_2$-DOX/AS1411, for magnetic resonance/fluorescence imaging-guided synergistic chemo-photothermal therapy for hypoxic solid tumors in vitro and in vivo. An example of this combination of photothermal therapy and radiotherapy comes from Yang et al, who designed WS$_2$-based nanocomposites with iron oxide nanoparticles (IONPs) and MnO$_2$ shell via self-assembly. Here, MnO$_2$ was used as a pH-activated T1 CA and IONPs as a pH-inert T2 CA to achieve tumor pH-responsive MRI. The strong NIR absorption of WS$_2$ enabled photoacoustic imaging capacity, while the near-infrared and X-ray absorption of WS$_2$ were performed for PTT and enhanced radiotherapy, respectively. More crucially, MnO$_2$ catalyzed overexpression of H$_2$O$_2$ produced O$_2$ to alleviate tumor hypoxia and so enhance therapeutic effects. Cao and colleagues prepared MnO$_2$/Cu$_2$S-siRNA nanoparticles by loading Cu$_2$S onto the surface of MnO$_2$ nanosheets and then modifying them with HSP 70 siRNA. Once NPs were taken up by tumor cells, MnO$_2$ nanosheets were reduced to Mn$^{2+}$ ions which enhance the MRI contrast and initiated the decomposition of H$_2$O$_2$ to O$_2$ to alleviate tumor hypoxia. The NIR absorption of Cu$_2$S can be used for PA and photothermal (PT) imaging. Under a single NIR laser irradiation, NPs exhibited a three-mode imaging-guided enhanced PTT/PDT due to siRNA-mediated blockade heat shock response as well as MnO$_2$-related amelioration of tumor hypoxia.

**MnO$_x$-Based Nanoparticles In Tumor Diagnosis And Therapy**

The oxidation state of manganese oxide can be distinguished using classical material science characterization techniques such as X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and so on. However, when the size of the material reaches the nanoscale, the broadening and weakening of the peak means that this characterization becomes extremely challenging. Therefore, some researchers described the nanostructures simply as MnO$_2$ to avoid inaccuracies. Rosenholm and colleagues modified amorphous MnO$_x$ with PVP and poly(acrylic acid) (PAA) to bring a negative charge to the surface (−25.7 ± 1.47 mV), while the hydrodynamic properties and biocompatibility were found to be significantly better than crystallization (MnO). Additionally, the relaxation time of the nanoprobe was approximately 10 times lower than that of the crystalline particles. Ren and colleagues used MnO$_x$ coated superparamagnetic iron oxide nanoparticles as gates to control the CPT release from mesoporous silica and so achieve the TME-responsive T1/T2 dual-mode MRI-guided pancreatic cancer chemotherapy both in vitro and in vivo. Similarly, Gao and colleagues labeled technetium-99 ($^{99m}$Tc) on the surface of the MnO$_x$-based mesoporous silica nanoparticles (MnO$_x$-MSN) to integrate SPECT and MRI imaging modalities for both excellent sensitivity and high spatial resolution. The radiolabeling yield was as high as 99.1 ±0.6%, while the r$_1$ value of the nanostructures could reach 6.60 mM$^{-1}$s$^{-1}$ as a result of the pH-responsive nature of MnO$_x$-MSN. Additionally, the drug loading rate of MnO$_x$-MSN to Dox was as high as 382 mg/g, while the degradation of MnO$_2$ in a weak acid environment triggers on-demand drug release. Zhang and colleagues ingeniously integrated MnO$_x$ NPs into hollow mesoporous carbon nanocapsules via an in situ framework redox method. In the weak acidic environment, the longitudinal relaxation of pH-sensitive
MnO\textsubscript{x} NPs increased 52.5 times to 10.5 mM\textsuperscript{−1}s\textsuperscript{−1}.\textsuperscript{130} The carbonaceous framework could not only react with MnO\textsubscript{x} to form MnO\textsubscript{x} NPs in situ but also could connect to the aromatic drug molecules through \pi-\pi stacking. Drug release behavior which was triggered by different pH and high intensity focused ultrasound (HIFU) systematically confirmed the findings of pH-/HIFU-triggered Dox on-demand release as well as enhanced cancer cell chemotherapy. In contrast, Dai and colleagues grew MnO\textsubscript{x} nanoparticles in situ on the surface of tantalum carbide (Ta\textsubscript{4}C\textsubscript{3}) MXene nanosheets and created further surface organic modification by soybean phospholipids (SP) for three-mode imaging-guiding PTT.\textsuperscript{131} Similarly, the integrated nanoparticles, MnO\textsubscript{x}/Ta\textsubscript{4}C\textsubscript{3}−SP, had TME-responsive T1-weighted MR imaging capabilities (see Figure 7A and B), while the photothermal conversion performance of Ta\textsubscript{4}C\textsubscript{3} endowed MnO\textsubscript{x}/Ta\textsubscript{4}C\textsubscript{3} NPs with photoacoustic imaging and photoconductive tumor ablation capabilities, in which tantalum was also used as a high-performance CT imaging contrast agent (see Figure 7C–E). This work provided a new strategy for both cancer diagnosis and photothermal therapy.

**Conclusion And Outlook**

MRI is the fastest growing molecular imaging technology due to its non-invasive nature, high spatial resolution, non-ionizing radiation, soft tissue imaging, and so on. In order to improve the sensitivity of MRI, the study of CAs has attracted wide attention. Furthermore, due to their good biocompatibility, relatively high magnetization spin and rapid water proton exchange rate, MONs, rather than Gd-based, have been developed as a T1 CA, and have a huge clinical significance for the detection and diagnosis of cancer. This review summarizes recent advances in MONs-related multimodal imaging CAs and nanoanostatic agents, including MnO, Mn\textsubscript{3}O\textsubscript{4}, MnO\textsubscript{2}, and MnO\textsubscript{x} as MR CAs in MRI, bimodal or multimodal imaging, and imaging-guided therapy.

While the broad prospects of the MONs nanoplatform have been noted, they are still in the early lab stage. Similar to all nanostructures, the small size of nanomaterials gives them excellent physical and chemical properties, but their nanotoxicity is still unclear. For MONs, whether or not the crystal structure weakens the neurotoxicity of manganese itself requires further study. More importantly, the more

![Figure 7](image-url)
functionality of a single nanoprobe is achieved at the expense of increasing complexity. The complex structures required to achieve versatility present enormous technical challenges in the construction and assembly of these nanoprobes, such as colloidal stability, controllability of experimental processes, reproducibility, and cost control. These challenges increase the difficulty of purifying the resulting nanoprobe, as well as the monodispersity of the final product, and lead to storage and shelf-life issues. These are all major challenges for the clinical transformation of MONs NPs.

Based on the evidence cited here, further research is needed to obtain a robust, reproducible experimental protocol, and then to fully characterize and verify the properties and functions of each component of the nanoprobes in various models in vitro and in vivo. In addition, monitoring the long-term toxicity, immunotoxicity, and neurotoxicity of NPs are also essential. Efficient delivery of NPs at specific locations in the body is currently a major obstacle to tumor imaging and therapy, while the screening of tumor markers is the key to addressing probe targeting specificity issues. As science and technology develop, if these problems can be effectively solved, the engineering MONs could be used as a safe nanoplatform for tumor diagnosis, monitoring, and treatment in clinic.

Acknowledgments
This work was supported, in part, by the National Key R&D Program of China under Grant No. 2018YFC0910602, the National Natural Science Foundation of China under Grant Nos. 11727813, 81627807, 81871397, 81701853, 81660505 and 81530058, the Fok Ying-Tong Education Foundation of China under Grant 161104, the Program for the Young Top-notch Talent of Shaanxi Province, the Research Fund for Young Star of Science and Technology in Shaanxi Province under Grant No. 2018KJXX-018, the Natural Science Basic Research Plan in Shaanxi Province of China under Grant No. 2018JM7072, and the Fundamental Research Funds for the Central Universities (JB181203).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science. 2003;302(5645):605–608. doi:10.1126/science.1090585
2. Zhang K, Chen HR, Li P, et al. Marriage strategy of structure and composition designs for intensifying ultrasound & MR & CT trimodal contrast imaging. ACS Appl Mater Inter. 2015;7 (33):18590–18599. doi:10.1021/acsami.5b04999
3. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452(7187):580–589. doi:10.1038/nature06917
4. Wang LHV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science. 2012;335(6075):1458–1462. doi:10.1126/science.1216210
5. Zhan YH, Shi SX, Ehlerding EB, et al. Radiolabeled, antibody-conjugated manganese oxide nanoparticles for tumor vasculature targeted positron emission tomography and magnetic resonance imaging. ACS Appl Mater Inter. 2017;9(44):38304–38312. doi:10.1021/acsami.7b12216
6. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008;60(11):1252–1265. doi:10.1016/j.addr.2008.03.018
7. Na HB, Song IC, Hyeon T. Inorganic nanoparticles for MRI contrast agents. Adv Mater. 2009;21(21):2133–2148. doi:10.1002/adma.v21:21
8. Lei M, Fu C, Cheng X, et al. Activated surface charge-reversal manganese oxide nanocubes with high surface-to-volume ratio for accurate magnetic resonance tumor imaging. Adv Funct Mater. 2017;27(30):1700978. doi:10.1002/adfm.201700978
9. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin N Am. 2005;43(5):887–989. doi:10.1016/j.rcl.2005.05.004
10. Zhao Z, Zhou Z, Bao J, et al. Octapod iron oxide nanoparticles as high-performance T2 contrast agents for magnetic resonance imaging. Nat Commun. 2013;4:2266. doi:10.1038/ncomms2266
11. Carvan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35(6):512–523. doi:10.1039/b510982p
12. Idee JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin N Am. 2009;47(5):855–869. doi:10.1016/j.rcl.2009.06.006
13. Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23(2):307–318. doi:10.1007/s00330-012-2597-9
14. Xiang Y, Li NL, Guo LJ, et al. Biocompatible and pH-sensitive MnO-loaded carbonaceous nanospheres (MnO@CNSs): a theranostic agent for magnetic resonance imaging-guided photothermal therapy. Carbon. 2018;136:113–124. doi:10.1016/j.carbon.2018.04.058
15. Bulte JWM. In vivo MRI cell tracking: clinical studies. Am J Roentgenol. 2009;193(2):314–325. doi:10.2214/AJR.09.3107
16. Kostura L, Kraitchman DL, Mackay AM, Pittenger MF, Bulte JWM. Ferric labeling of mesenchymal stem cells inhibits chondrogenesis but not adipogenesis or osteogenesis. NMR Biomed. 2004;17(7):513–517. doi:10.1002/nbm.925
17. Neves HR, Bini RA, Barbosa JHO, Salmon CEG, Varanda LC. Dextran-coated antiferromagnetic MnO nanoparticles for a T1-MRI contrast agent with high colloidal stability. Part Part Syst Char. 2016;33(3):167–176. doi:10.1002/ppsc.201500251
18. Hu H, Liu SL, Li D, et al. The synthesis of lanthanide-doped GdVO4 ultrathin nanosheets with great optical and paramagnetic properties for FRET biodetection and in vivo MR imaging. J Mater Chem B. 2014;2(25):3998–4007. doi:10.1039/C4TB00144C
19. Fitsanakis VA, Zhang N, Avison MJ, Gore JC, Aschner JL, Aschner M. The use of magnetic resonance imaging (MRI) in the study of manganese neurotoxicity. Neurotoxicology. 2006;27(5):798–806. doi:10.1016/j.neuro.2006.03.001
20. Takeda A. Manganese action in brain function. Brain Res Rev. 2003;41(1):79–87.
21. Guilarte TR. Manganese neurotoxicity: new perspectives from behavioral, neuroimaging, and neuropathological studies in humans and non-human primates. *Front Aging Neurosci*. 2013;5:23. doi:10.3389/fnagi.2013.00023

22. Pan D, Caruthers SD, Hu G, et al. Ligand-directed nanobiaryl as theranostic agent for drug delivery and manganese-based magnetic resonance Imaging of vascular targets. *J Am Chem Soc*. 2008;130(29):9186–9187. doi:10.1021/ja801482d

23. Pan DPJ, Schnieder AH, Wickline SA, Lanza GM. Manganese-based MRI contrast agents: past, present, and future. *Tetrahedron*. 2011;67(44):8431–8444. doi:10.1016/j.tet.2011.07.072

24. Peng JR, Dong ML, Ran B, et al. “One-for-All”-type, biodegradable prussian blue/manganese dioxide hybrid nanocrystal for trimodal imaging-guided photothermal therapy and oxygen regulation of breast cancer. *ACS Appl Mater Inter*. 2017;9(9):13875–13886. doi:10.1021/acsami.7b01365

25. Hsu BYW, Kirby G, Tan A, Seifalian AM, Li X, Wang J. Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications. *RSC Adv*. 2016;6(51):45462–45474. doi:10.1039/C6RA04421B

26. Garcia-Hevia L, Banobre-Lopez M, Gallo J. Recent progress on manganese-based nanostuctures as responsive MRI contrast agents. *Chem-Eur J*. 2019;25(2):431–441. doi:10.1002/chem.201802851

27. Li J, Wu C, Hou P, Zhang M, Xu K. One-pot preparation of hydrophilic manganese oxide nanoparticles as T1 nano-contrast agent for molecular magnetic resonance imaging of renal carcinoma in vitro and in vivo. *Biosens Bioelectron*. 2018;102:1–8. doi:10.1016/j.bios.2017.10.047

28. Huang HT, Yue T, Xu K, Golzarian J, Yu JH, Huang J. Fabrication and evaluation of tumor-targeted positive MRI contrast agent based on ultrasmall MnO nanoparticles. *Colloid Surf B*. 2015;131:148–154.

29. Hsu BYW, Wang M, Zhang Y, et al. Silica-F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T1-magnetic resonance relaxivity. *Nanoscale*. 2014;6(1):293–299. doi:10.1039/c3nr04378a

30. Costanzo M, Scolaro L, Berlier G, et al. Cell uptake and intra-cellular fate of phospholipidic manganese-based nanoparticles. *Int J Pharmaceut*. 2016;508(1–2):83–91. doi:10.1016/j.ijpharm.2016.05.019

31. Chevalier P, Walter A, Garofalo A, et al. Tailored biological retention and efficient clearance of pegylated ultra-small MnO nanoparticles as positive MRI contrast agents for molecular imaging. *J Mater Chem B*. 2014;2(13):1779–1790. doi:10.1039/C3TB21634A

32. Huang HT, Yue T, Xu YY, et al. PEGylation of MnO nanoparticles via catechoth-Mn chelation to improving T1-weighted magnetic resonance imaging application. *J Appl Polym Sci*. 2015;132(31):42360. doi:10.1002/app.42360

33. Gallo J, Alain IS, Lavdas I, Wylezinska-Arridge M, Aboagye EO, Long NJ. RGD-targeted MnO nanoparticles as T1 contrast agents for cancer imaging – the effect of PEG length in vivo. *J Mater Chem B*. 2014;2(7):866–876. doi:10.1039/C3TB21422B

34. Chen N, Shao C, Qi Y, et al. Folic acid-conjugated MnO nanoparticles as a T1 contrast agent for magnetic resonance imaging of tiny brain gliomas. *ACS Appl Mater Interfaces*. 2014;6(22):19850–19857. doi:10.1021/am505223t

35. Hu X, Ji Y, Wang M, et al. Water-soluble and biocompatible MnO@PVP nanoparticles for MR imaging in vitro and in vivo. *J Biomed Nanotechnol*. 2013;9(6):976–984. doi:10.1166/jbn.2013.1602

36. Douglas FJ, MacLaren DA, Tuna F, Holmes WM, Berry CC, Murie M. Formation of octopod MnO nanoparticles with enhanced magnetic properties through kinetically-controlled thermal decomposition of polynuclear manganese complexes. *Nanoscale*. 2014;6(1):172–176. doi:10.1039/c3nr04832b

37. Peng YK, Lui CNP, Chen YW, et al. Engineering of single magnetic particle carrier for living brain cell imaging: a tunable T1/T2-dual-modal contrast agent for magnetic resonance imaging application. *Chem Mater*. 2017;29(10):4411–4417. doi:10.1021/acs.chemmater.7b00884

38. Peng E, Wang FH, Tan SH, Zheng BW, Li SFX, Xue JY. Tailoring a two-dimensional graphene oxide surface: dual T1 and T2 MR contrast agent materials. *J Mater Chem B*. 2015;3(28):5676–5682. doi:10.1039/C5TB00922B

39. Zheng YY, Zhang H, Hu YP, Bai L, Xue JY. MnO nanoparticles with potential application in magnetic resonance imaging and drug delivery for myocardial infarction. *Int J Nanomed*. 2018;13:6177–6188. doi:10.2147/IJN.S176404

40. Chen N, Shao C, Li S, et al. Cy5.5 conjugated MnO nanoparticles for magnetic resonance/near-infrared fluorescence dual-modal imaging of brain gliomas. *J Colloid Interf Sci*. 2015;457:27–34. doi:10.1016/j.jcis.2015.06.046

41. Hsu BYW, Ng M, Tan A, et al. pH-activatable MnO-based fluorescence and magnetic resonance bimodal nanoprobe for cancer imaging. *Adv Healthc Mater*. 2016;5(6):721–729. doi:10.1002/adhm.201500908

42. Lai JX, Wang TJ, Wang H, Shi FQ, Gu W, Ye L. MnO nanoparticles with unique excitation-dependent fluorescence for multicolor cellular imaging and MR imaging of brain glioma. *Microchim Acta*. 2018;185(4):244. doi:10.1007/s00604-018-7779-5

43. Banerjee A, Bertolesi GE, Ling CC, et al. Bifunctional pyrroldin-2-one terminated manganese oxide nanoparticles for combined magnetic resonance and fluorescence imaging. *ACS Appl Mater Interfaces*. 2019;11(14):13069–13078. doi:10.1021/acsami.8b12762

44. Li S, Shao C, Gu W, et al. Targeted imaging of brain gliomas using multifunctional Fe3O4/MnO nanoparticles. *RSC Adv*. 2015;5(42):33636–33645. doi:10.1039/C5RA01069A

45. Liu Y, Lv XL, Liu H, et al. Porous gold nanocluster-decorated manganese monoxide nanocomposites for microenvironment-activatable MR/photoacoustic/CT tumor imaging. *Nanoscale*. 2018;10(8):3631–3638. doi:10.1039/C7nr08553d

46. Liu JN, Bu WB, Shi JL. Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia. *Chem Rev*. 2017;117(9):6160–6224. doi:10.1021/acs.chemrev.6b00525

47. Ni DL, Jiang DW, Valdivinios HF, et al. Biore sponsive polycyto-metallate cluster for redox-activated photoacoustic imaging-guided photothermal cancer therapy. *Nano Lett*. 2017;17(5):3282–3289. doi:10.1021/acs.nanolett.7b00995

48. Lu Y, Zhang L, Li J, et al. MnO nanocrystals: a platform for integration of MRI and genuine autophagy induction for chemotherapy. *Adv Funct Mater*. 2013;23(12):1534–1546. doi:10.1002/adfm.201202233

49. Wei J, Yu C, Wang L, et al. Cytotoxicity of mitochondrion-targeting silica-coated manganese oxide nanoparticles. *Sci China Chem*. 2015;58(10):1537–1543. doi:10.1007/s11426-015-5374-1

50. Howell M, Mallela J, Wang C, et al. Manganese-loaded lipid-micellar thanosics for simultaneous drug and gene delivery to lungs. *J Control Release*. 2013;167(2):210–218. doi:10.1016/j.jconrel.2013.01.029

51. Wang D, Lin H, Zhang G, et al. Effective pH-activated theranostic platform for synchronous magnetic resonance imaging diagnosis and chemotherapy. *ACS Appl Mater Interfaces*. 2018;10(37):31114–31123. doi:10.1021/acsami.8b11408

52. Abbasí AZ, Prasad P, Cai P, et al. Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer. *J Control Release*. 2015;209:186–196. doi:10.1016/j.jconrel.2015.04.020

53. Wang S, Zhang Q, Yang P, et al. Manganese oxide-coated carbon nanotubes as dual-modality lymph mapping agents for photothermal therapy of tumor metastasis. *ACS Appl Mater Interfaces*. 2016;8(6):3736–3743. doi:10.1021/acsami.5b08087
54. Zhou LH, Wu YY, Meng XQ, et al. Dye-anchored MnO nanoparticles targeting tumor and inducing enhanced phototherapy effect via mitochondria-mediated pathway. Small. 2018;14(36):1801008. doi:10.1002/smll.201801008
55. He DG, He XX, Wang KM, et al. Redox-responsive degradable honeycomb manganese oxide nanostructures as effective nanocarriers for intracellular glutathione-triggered drug release. Chem Commun. 2015;51(4):776–779. doi:10.1039/C4CC08172B
56. Hu H, Dai AT, Sun J, et al. Aptamer-conjugated Mn3O4@SiO2 core-shell nanoparticles for targeted magnetic resonance imaging. Nanoscale. 2013;5(21):10447–10454. doi:10.1039/c3nr03490a
57. Yang X, Zhou Z, Wang L, Tang C, Yang H, Yang S. Folate conjugated Mn3O4@SiO2 nanoparticles for targeted magnetic resonance imaging in vivo. Mater Res Bull. 2014;57:97–102. doi:10.1016/j.materresbull.2014.05.023
58. Wang P, Yang J, Zhou BQ, et al. Antifouling manganese oxide nanoparticles: synthesis, characterization, and applications for enhanced MR imaging of tumors. ACS Appl Mater Inter. 2017;9(1):47–53. doi:10.1021/acsami.6b03844
59. Luo Y, Yang J, Li J, et al. Facile synthesis and functionalization of manganese oxide nanoparticles for targeted T1-weighted MR imaging. Colloids Surf B Biointerfaces. 2015;136:506–513. doi:10.1016/j.colsurfb.2015.09.053
60. Sun W, Zhang J, Zhang C, et al. Construction of hybrid alginate nanogels loaded with manganese oxide nanoparticles for enhanced tumor magnetic resonance imaging. ACS Macro Lett. 2018;7(2):137–142. doi:10.1021/acsmacrolett.7b00999
61. Lee J, Kumari N, Kim SM, et al. Anchoring ligand-effect on bright contrast-enhancing property of hollow Mn3O4 nanoparticle in T1-weighted magnetic resonance imaging. Chem Mater. 2018;30(12):4056–4064. doi:10.1021/acs.chemmater.8b00854
62. Guo W, Qi Y, Zhang Y, Ma L, Yu D, Zhan J. Biocompatible caramellized carbonaceous nanospheres supported paramagnetic ultrathin manganese oxide nanosheets via self-sacrificing reduction as a MRI contrast agent for liver imaging. Carbon. 2016;110:321–329. doi:10.1016/j.carbon.2016.09.030
63. Xiao J, Tian YM, Yang C, et al. Ultrahigh relaxivity and safe probes of manganese oxide nanoparticles for in vivo imaging. Sci Rep. 2013;3:3424. doi:10.1038/srep03424
64. Hu H, Zhang C, An L, et al. General protocol for the synthesis of functionalized magnetic nanoparticles for magnetic resonance imaging from protected metal-organic precursors. Chemistry. 2014;20(23):7160–7167. doi:10.1002/chem.201305072
65. Li JC, Hu Y, Sun WJ, Luo Y, Shi XY, Shen MW. Facile preparation of hyaluronic acid-modified Fe3O4@Mn3O4 nanocomposites for targeted T-1/T-2 dual-mode MR imaging of cancer cells. RSC Adv. 2016;6(42):35295–35300. doi:10.1039/c6ra05648B
66. Kim MH, Son HY, Kim GT, Park K, Huh YM, Haam S. Redoxable heterocarbons modifying magnetic relaxation switch for activatable T-1 and T-2 dual-mode magnetic resonance imaging. Biomaterials. 2016;101:121–130. doi:10.1016/j.biomaterials.2016.05.054
67. Zhu YJ, Li HS, Xiong ZJ, et al. Polyethyleneimine-coated manganese oxide nanoparticles for targeted tumor PET/MR imaging. ACS Appl Mater Inter. 2018;10(41):34954–34964. doi:10.1021/acsami.8b02355
68. Fonsatti E, Nicolay HJM, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antigen-body-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010;86(1):12–19. doi:10.1093/crv/cvp332
69. Zhan Y, Ehlerding EB, Shi S, et al. Intrinsically zincium-89-labeled manganese oxide nanoparticles for in vivo dual-modality positron emission tomography and magnetic resonance imaging. J Biomed Nanotechnol. 2018;14(5):900–909. doi:10.1166/jbn.2018.2498
70. Zhan Y, Zhan W, Li H, et al. In vivo dual-modality fluorescence and magnetic resonance imaging-guided lymph node mapping with good biocompatibility manganese oxide nanoparticles. Molecules. 2017;22(12):2208. doi:10.3390/molecules22122208
71. Fang C, Zhang M. Nanoparticle-based theranostics: integrating diagnostic and therapeutic potentials in nanomedicine. J Control Release. 2010;146(1):2–5. doi:10.1016/j.jconrel.2010.05.013
72. Wang A, Guo M, Wang N, et al. Redox-mediated dissolution of paramagnetic nanoloids to achieve a smart theranostic system. Nanoscale. 2014;6(10):5270–5278. doi:10.1039/c3nr05687b
73. Zhang Y, Tan J, Long M, et al. An emerging dual collaborative strategy for high-performance tumor therapy with mesoporous silicon nanotubes loaded with Mn3O4. J Mater Chem B. 2016;4(47):7406–7414. doi:10.1039/C5TB01789F
74. Agostini P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–281. doi:10.3322/caac.20141
75. Nafiujiaman M, Nurunnabi M, Kang S-H, Recek GR, Khan HA, Lee Y-K. Ternary graphene quantum dot–polypolyamine–mn3O4 nanoparticles for optical imaging guided photodynamic therapy and T-1-weighted magnetic resonance imaging. J Mater Chem B. 2015;3(28):5815–5823. doi:10.1039/C5TB00479A
76. Ding X, Liu JH, JQ L, et al. Polydopamine coated manganese oxide nanoparticles with ultrahigh relaxivity as nanotheranostic agents for magnetic resonance imaging guided synergetic chemo-photothermal therapy. Chem Sci. 2016;7(11):6695–6700. doi:10.1039/c6sc01320a
77. Liu Y, Zhang G, Guo Q, et al. Artificially controlled degradable inorganic nanomaterial for cancer theranostics. Biomaterials. 2017;112:204–217. doi:10.1016/j.biomaterials.2016.10.028
78. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991;51 (3):794–798.
79. Xu J, Han W, Yang P, et al. Tumor microenvironment-responsive mesoporous MnO2-coated upconversion nanoplatform for self-enhanced tumor theranostics. Adv Funct Mater. 2018;28(36):1803804. doi:10.1002/adfm.201803804
80. Lin LS, Song JB, Song L, et al. Simultaneous fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed. 2018;57(18):4902–4906. doi:10.1002/anie.201712027
81. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003;195(1):1–16. doi:10.1016/s0304-3835(03)00012-0
82. Zhao ZL, Fan HH, Zhou GF, et al. Activatable fluorescence/MRI bimodal platform for tumor cell imaging via MnO2 nanosheet-aptamer nanoprobe. J Am Chem Soc. 2014;136(32):11220–11223. doi:10.1021/ja5029364
83. Shi W, Song B, Shi W, et al. Bimodal phosphorescence-magnetic resonance imaging probes for glutathione based on MnO2 nanosheet-Ru(II) complex nanoarchitecture. ACS Appl Interfaces. 2018;10(33):27681–27691. doi:10.1021/acs.interfaces.8b00872
84. Duan B, Wang D, Wu H, et al. Core–shell structured Fe3O4/C@MnO2 nanoparticles as pH responsive T1-T2* dual-modal contrast agents for tumor diagnosis. ACS Biomater Sci Eng. 2018;4(8):3047–3054. doi:10.1021/acsbiomater.8b00287
85. Eubank TD, Roberts RD, Khan M, et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res. 2009;69(5):2133–2140. doi:10.1158/0008-5472. CAN-08-1405
86. Chen Y, Ye D, Wu M, et al. Break-up of two-dimensional MnO2 nanosheets promotes ultrasensitive pH-triggered theranostics of cancer. Adv Mater. 2014;26(41):7019–7026. doi:10.1002/adma.201402572
87. Song M, Liu T, Shi C, Zhang X, Chen X. Biocjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10(1):633–647. doi:10.1021/acsnano.5b06779
88. Hao Y, Wang L, Zhang B, et al. Manganese dioxide nanosheets-based redox/pH-responsive drug delivery system for cancer theranostic application. Int J Nanomedicine. 2016;11:1759–1778. doi:10.2147/IJN.S98832
89. Hao Y, Wang L, Zhang B, et al. Multifunctional nanosheets based on folic acid modified manganese oxide for tumor-targeting theranostic application. Nanotechnology. 2016;27(2):025101. doi:10.1088/0957-4484/27/36/36202
90. Pan J, Wang Y, Pan H, et al. Mimicking drug-substrate interaction: a smart bioinspired technology for the fabrication of theranostic nanoprobes. Adv Funct Mater. 2017;27(3):1603440. doi:10.1002/adfm.201603440
91. Zhang M, Xing L, Ke H, et al. MnO2-based nanoplatform serves as drug vehicle and MRI contrast agent for cancer theranostics. ACS Appl Mater Interfaces. 2017;9(13):11337–11344. doi:10.1021/acsami.6b15247
92. Meng L, Cheng Y, Gan S, et al. Facile deposition of manganese dioxide to albumin-bound paclitaxel nanoparticles for modulation of hypoxic tumor microenvironment to improve chemoradiation therapy. Mol Pharm. 2018;15(2):447–457. doi:10.1021/acs.molpharmaceut.7b00808
93. Shi Y, Guennane F, Wang X, Helary C, Coradin T. MnO2-gated nanoplatforms with targeted controlled drug release and contrast-enhanced MRI properties: from 2D cell culture to 3D biomimetic hydrogels. Nanotheranostics. 2018;2(4):403–416. doi:10.7150/ntno.28046
94. Wu Y, Li D, Zhou F, et al. Versatile in situ synthesis of MnO2 nanolayers on upconversion nanoparticles for modulation of hypoxic tumor microenvironment to improve chemoradiation therapy. Chem Sci. 2018;9(24):5427–5434. doi:10.1039/c8sc00490k
95. Song R, Zhang M, Liu Y, et al. A multifunctional nanotheranostic for the intelligent MRI diagnosis and synergistic treatment of hypoxic tumor. Biomaterials. 2018;175:123–133. doi:10.1016/j.biomaterials.2018.05.018
96. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58. doi:10.1038/nrc706
97. Zhang C, Bu WB, Ni DL, et al. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction. Angew Chem Int Ed. 2016;55(6):2101–2106. doi:10.1002/anie.201510031
98. Turan IS, Yildiz D, Turksoy A, Gunaydin G, Akkaya EU. A bifunctional photosensitizer for enhanced fractional photodynamic therapy: singlet oxygen generation in the presence and absence of light. Angew Chem Int Ed. 2016;55(8):2875–2878. doi:10.1002/anie.201511345
99. Hao Y, Zhang B, Zheng C, et al. Multifunctional nanoplatform for enhanced photodynamic cancer therapy and magnetic resonance imaging. Colloids Surf B Biointerfaces. 2017;151:384–393. doi:10.1016/j.colsurfb.2016.10.039
100. Meng HM, Lu LM, Zhao XH, et al. Multiple functional nanoprobe for contrast-enhanced bimodal cellular imaging and targeted therapy. Anal Chem. 2015;87(8):4448–4454. doi:10.1021/acs.analchem.5b00337
101. Chu CC, Lin HR, Liu H, et al. Tumor microenvironment-triggered supramolecular system as an in situ responsive theranostic generator for cancer phototherapy. Adv Mater. 2017;29(23):1605928. doi:10.1002/adma.201700681
102. Sun QQ, He F, Sun CQ, et al. Honeycomb-satellite structured pH/H2O2-responsive degradable nanoplatform for efficient photodynamic therapy and multimodal imaging. ACS Appl Mater Inter. 2018;10(40):33901–33912. doi:10.1021/acsami.8b02070
103. Liu H, Liu Y, Chu CC, et al. Intelligent albumin-stabilized manganese dioxide nanocomposites for tumor microenvironment responsive phototherapy. J Biomed Nanotechnol. 2017;13(10):1321–1332. doi:10.1166/jbn.2017.2450
104. Lin T, Zhao X, Zhao S, et al. O2-generating MnO2 nanoparticles for enhanced photodynamic therapy of bladder cancer by ameliorating hypoxia. Theranostics. 2018;8(4):990–1004. doi:10.7150/thno.22465
105. Ma Z, Jia X, Bai J, et al. MnO2Gatekeeper: an Intelligent and O2-evolving shell for preventing premature release of high cargo payload core, overcoming tumor hypoxia, and acidic H2O2-sensitive MRI. Adv Funct Mater. 2017;27(4):1604258. doi:10.1002/adfm.201604258
106. Liu J, Du P, Liu T, et al. A black phosphorus/manganese dioxide nanoplatform: oxygen self-supply monitoring, photodynamic therapy enhancement and feedback. Biomaterials. 2019;192:179–188. doi:10.1016/j.biomaterials.2018.10.018
107. He ZM, Xiao Y, Zhang JR, Zhang PH, Zhu JJ. In situ formation of large pore silica-MnO2 nanocomposites with H2O2/H2O2 sensitivity for O2- elevated photodynamic therapy and potential MR imaging. Chem Commun. 2018;54(24):2962–2965. doi:10.1039/C7CC9532E
108. Zhu W, Zhang L, Yang Z, et al. An efficient tumor-inducible nanotheranostics for magnetic resonance imaging and enhanced photodynamic therapy. Chem Eng J. 2019;358:969–979. doi:10.1016/j.cej.2018.10.102
109. Liang RJ, Liu LL, He HM, et al. Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials. 2018;177:149–160. doi:10.1016/j.biomaterials.2018.05.051
110. Hao YW, Zhang BX, Zheng CX, et al. Multifunctional nanoplat-form for enhanced photodynamic cancer therapy and magnetic resonance imaging. Colloids Surf B Biointerfaces. 2017;151:384–393. doi:10.1016/j.colsurfb.2016.10.039
111. Hu DR, Chen LJ, Qu Y, et al. Oxygen-generating hybrid polymeric nanoparticles with encapsulated doxorubicin and chlorin e6 for trinodal imaging-guided combined chemo-photodynamic therapy. Theranostics. 2018;8(6):1558–1574. doi:10.7150/thno.22989
112. Xu JT, Han W, Yang PP, et al. Tumor microenvironment-responsive mesoporous MnO2-coated upconversion nanoplat-form for self-enhanced tumor theranostics. Adv Funct Mater. 2018;28(36):1803804. doi:10.1002/adfm.201803804
113. Bi HT, Dai YL, Yang PP, et al. Glutathione and H2O2 consumption promoted photodynamic and chemotherapy based on biodegradable MnO2-Pt@Au-25 nanosheets. Chem Eng J. 2019;356:543–553. doi:10.1016/j.cej.2018.09.076
114. Zhang C, Chen W-H, Liu L-H, Qiu W-X, Yu W-Y, Zhang X-Z. An O2 self-supplementing and reactive-oxygen-species-circulating amplified nanoplat-form via H2O/H2O2 splitting for tumor imaging and photodynamic therapy. Adv Funct Mater. 2017;27(43):1700626. doi:10.1002/adfm.2017043
115. Deng YY, Li ED, Cheng XJ, et al. Facile preparation of hybrid core-shell nanorods for photothermal and radiation combined therapy. Nanoscale. 2016;8(7):3895–3899. doi:10.1039/c5nr09102k
116. Fan WP, Yung B, Huang P, Chen XY. Nanotechnology for multidrug synergistic cancer therapy. Chem Rev. 2017;117(22):13566–13638. doi:10.1021/acs.chemrev.7b00258
117. Chen XY, Gambhir SS, Cheon J. Theranostic Nanomedicine. Accounts Chem Res. 2011;44(10):841. doi:10.1021/ar200321d
118. Liu Z, Zhang SJ, Lin H, et al. Theranostic 2D ultrathin MnO2 nanosheets with fast responsibility to endogenous tumor microenviron-ment and exogenous NIR irradiation. Biomaterials. 2018;155:54–63. doi:10.1016/j.biomaterials.2017.11.015
119. Fu DD, Ding XG, Wu J, Li CY, Wang QB, Jiang J. Cationic polyelec-tolyte mediated synthesis of mno2-ba Char@Au-25 nanosheets. Adv Funct Mater. 2018;28(10):1574. doi:10.7150/thno.22989
120. Cai XJ, Gao W, Ma M, et al. A Prussian blue-based core-shell hollow-structured mesoporous nanoparticle as a smart theranostic agent with ultra-high pH-responsive longitudinal relaxivity. Adv Mater. 2015;27(41):6382–6389. doi:10.1002/adma.201503381
121. Chen WH, Luo GF, Lei Q, et al. Overcoming the heat endurance of tumor cells by interfering with the anaerobic glycolysis metabolism for improved photothermal therapy. *ACS Nano*. 2017;11(2):1419–1431. doi:10.1021/acsnano.6b06658

122. Jin LH, Liu JH, Tang Y, et al. MnO2-functionalized Co-P nanocomposite: a new theranostic agent for pH-triggered T-1/T-2 dual-modality magnetic resonance imaging-guided chemo-photothermal synergistic therapy. *ACS Appl Mater Inter*. 2017;9(48):41648–41658. doi:10.1021/acsami.7b10608

123. Li SN, Zhang LY, Chen XJ, et al. Selective growth synthesis of ternary janus nanoparticles for imaging-guided synergistic chemo- and photothermal therapy in the second NIR window. *ACS Appl Mater Inter*. 2018;10(21):17732–17741. doi:10.1021/acsami.8b05050

124. Zhang TT, Xu CH, Zhao W, et al. A redox-activated theranostic nanoagent: toward multi-mode imaging guided chemo-photothermal therapy. *Chem Sci*. 2018;9(33):6749–6757. doi:10.1039/c8sc02446d

125. Yang GB, Zhang R, Liang C, et al. Manganese dioxide coated WS2@Fe3O4@SiO(2) nanocomposites for pH-responsive MR imaging and oxygen-elevated synergic therapy. *Small*. 2018;14(2):1702664. doi:10.1002/smll.201702664

126. Cao Y, Meng XD, Wang DD, et al. Intelligent MnO2/Cu2-xS for multimode imaging diagnostic and advanced single-laser irradiated photothermal/photodynamic therapy. *ACS Appl Mater Inter*. 2018;10(21):17732–17741. doi:10.1021/acsami.8b05050

127. Rosenholm JM, Korpi RM, Lammentausta E, et al. Novel, fast-processed crystalline and amorphous manganese oxide nanoparticles for stem cell labeling. *Inorg Chem Front*. 2015;2(7):640–648. doi:10.1039/C5QI00033E

128. Ren SS, Yang J, Ma L, et al. Ternary-responsive drug delivery with activatable dual modal contrast-enhanced in vivo imaging. *ACS Appl Mater Inter*. 2018;10(38):31947–31958. doi:10.1021/acsami.8b10564

129. Gao H, Liu X, Tang W, et al. (99m)Te-conjugated manganese-based mesoporous silica nanoparticles for SPECT, pH-responsive MRI and anti-cancer drug delivery. *Nanoscale*. 2016;8(47):19573–19580. doi:10.1039/c6nr07062k

130. Zhang SJ, Qian XQ, Zhang LL, Peng WJ, Chen Y. Composition-property relationships in multifunctional hollow mesoporous carbon nanosystems for PH-responsive magnetic resonance imaging and on-demand drug release. *Nanoscale*. 2015;7(17):7632–7643. doi:10.1039/c5nr00451a

131. Dai C, Chen Y, Jing XX, et al. Two-dimensional tantalum carbide (MXenes) composite nanosheets for multiple imaging-guided photothermal tumor ablation. *ACS Nano*. 2017;11(12):12696–12712. doi:10.1021/acsnano.7b07241